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Abstract 
Infections with Campylobacter jejuni are the leading cause of food borne bacterial 
gastroenteritis in most developed countries. The symptoms associated with 
campylobacteriosis range from mild enteritis to severe diarrhoea, and secondary 
symptoms can occur, including reactive arthritis and Guillain-Barré syndrome. C. jejuni 
pathogenesis is not fully understood but previous studies have shown that the bacterial 
surface is crucial for the virulence of this organism. In this thesis, we have focused on 
C. jejuni and its interaction with the human host.  
 
In the first study, multilocus sequence typing (MLST) was used to determine the 
diversity and population structure of C. jejuni isolates from Danish patients and to 
determine the association between multilocus sequence typing types and different 
clinical symptoms, including gastroenteritis, Guillain-Barré syndrome and reactive 
arthritis. 51 sequence types (STs) were identified within 18 clonal complexes (CCs). 
ST-21, ST-45 and ST-22 were the most frequent clonal complexes isolated and the GBS 
isolates grouped significantly into ST-22 clonal complex. There was no significant 
clustering of the reactive arthritis isolates.   
 
In the second part, we screened an expression library of NCTC 11168 C. jejuni genes 
for highly immunogenic proteins using antibodies raised in rabbit against a clinical 
isolate of C. jejuni serotype 2. This identified 52 highly reactive clones, which 
represented 25 different genes after sequencing. We examined some of them as vaccine 
candidates and for possible relation to virulence. Particularly one protein showed 
promising results as vaccine candidate in a mice immunization experiment and another 
protein could be important for adhesion of C. jejuni to epithelial cells and therefore 
human host interaction. The library was subsequently screened for genes expressing 
proteins involved in virulence-associated phenotypes, such as autoagglutination, 
biofilm-formation and adhesion to epithelial cells. Several interesting genes were 
identified but further work needs to be done on this part.  
 
In the last part, we studied a putative fibronectin binding protein (Cj1349c). Fibronectin 
(Fn) is a glycoprotein present in the regions of cell-to-cell contact in the gastrointestinal 
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epithelium and a potential binding site for pathogens. We investigated the protein, 
which was both expressed and studied in E. coli and expressed and purified from E. 
coli, for its ability to bind Fn using an ELISA assay. The assays revealed a binding of 
Cj1349c to Fn and we suggests that the Cj1349c protein has a role in attachment to host 
epithelial cells via Fn binding.   
 
In conclusion, population structure of Danish isolates was diverse but there was a 
significant grouping of GBS isolates. Furthermore, a possible new vaccine candidate, a 
putative new virulence factor and a new Fn binding protein were identified in this study.   
 
 
 
 
 
 
 5 
Dansk resumé 
Infektioner med Campylobacter jejuni er den mest almindelige årsag til bakterielle 
fødevarebårne infektioner i industrialiserede lande. Symptomerne spænder fra mild til 
alvorlig diarré og følgesygdomme som Guillain-Barré syndrom og reaktiv artrit kan 
opstå. Viden om C. jejunis patogenese er ikke fuldt ud forstået, men tidligere studier har 
vist at bakteriens overflade er afgørende for organismens virulens. I denne afhandling 
har vi fokuseret på C. jejuni og dens interaktion med den humane vært.   
 
I det første studie brugte vi Multilokus sekvenstypning (MLST) for at bestemme 
diversiteten og populationsstrukturen af C. jejuni isolater fra danske patienter og for at 
bestemme associationen mellem multilokus sekvenstyper og forskellige kliniske 
symptomer, inklusiv Guillain-Barré syndrom og reaktiv artrit. 51 sekvenstyper (STer) 
blev identificeret fordelt på 18 klonale komplekser (KKer). ST-21, ST-45 og ST-22 blev 
isoleret hyppigst og GBS isolaterne grupperede sig signifikant i ST-22 klonal komplex. 
Der var ingen signifikant gruppering af reaktiv artrit isolaterne.  
  
I den anden del screenede vi et ekspressionsbibliotek af NCTC 11168 C. jejuni gener 
for  meget immunogene proteiner ved at bruge antistoffer produceret i en kanin mod et 
klinisk isolat af C. jejuni serotype 2. Det resulterede i 52 meget reaktive kloner der 
repræsenterede 25 forskellige gener efter sekventering. We eksaminerede nogle af dem 
som vaccinekandidater og for en mulig relation med virulens. Specielt et protein viste 
lovende resultater som vaccine kandidat og et andet protein kunne have betydning for 
C. jejunis fasthæftelse til epitelceller og derved værtsinteraktion. Biblioteket blev 
efterfølgende screenet for proteiner involveret i virulens-associerede fænotyper som 
autoagglutination, biofilmdannelse og fasthæftelse til epitelceller. Flere interessante 
gener blev identificeret, men mere arbejde mangler på denne del.    
 
I den sidste del studerede vi et muligt fibronektinbindende protein (Cj1349c). 
Fibronektin (Fn) er et glykoprotein i regionerne af celle til celle kontakt i tarmepitelet 
og derfor et potentielt bindingssted for patogener. Vi undersøgte proteinet, der både 
blev udtrykt i E. coli samt udtrykt og oprenset fra E. coli, for dets evne til at binde Fn 
ved at bruge et ELISA assay. Assayet viste at Cj1349c bandt til fibronektin og vi 
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foreslår at proteinet Cj1349c spiller en rolle i fasthæftelsen til epitelceller via 
Fnbinding.  
 
Populationsstrukturen af danske isolater var divers, men der var en signifikant 
gruppering af GBS isolater. Ydermere blev en mulig ny vaccinekandidat, en ny mulig 
virulensfaktor samt et nyt fibronektinbindende protein identificeret i dette studie.  
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Aim and outline 
The aim of this thesis was to study the interactions between Campylobacter and the 
human host, by 1) study the population structure and clustering of C. jejuni isolates 
from enteritis and sequela, and 2) identify new genes involved in C. jejuni virulence.  
 
A general introduction to C. jejuni, its epidemiology and pathogenesis is given in 
chapter 1. An brief overview of the experimental work is given in chapter 2, followed 
by the obtained results presented in four separate chapters. Chapter 3 contains a paper 
of multilocus sequence typing and clustering analysis of C. jejuni clinical isolates. 
Chapter 4 and 5 contains results obtained by screening an E. coli open reading frame 
library of C. jejuni genes by using a novel method with antisera against C. jejuni   
(manuscript 2) and by using different virulence associated assays (manuscript 3). 
Chapter 6 contains manuscript 4 where results of a fibronectin binding protein are 
described. Chapter 7 is a general discussion of the work presented in thesis and 
suggestions for future research. Finally is a conclusion of the main results obtained. All 
references, including those cited in the paper and manuscripts, are found in the 
references at the end of the thesis.     
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1. Introduction 
1.1 Taxonomy, biology and epidemiology  
1.1.1 Taxonomy 
In 1886, Theodor Escherish identified a spiral shaped bacteria in stool sample from 
neonates with diarrhoeal and this was the first description of Campylobacter (Skirrow 
and Butzler, 2000). In 1906, two British veterinary surgeons reported the presence of 
several novel “Vibrio” species in a range of animals and in 1947 Vincent and colleagues 
isolated the organism (Vincent et al., 1947). Campylobacter were initially classified as 
Vibrio spp. due to spiral morphologi, but Sebald and Véron postulated in 1963 a new 
genus, Campylobacter (Sebald and Véron, 1963). The genus contains 15 species and six 
subspecies and belongs to the epsilon class of proteobacteria, which also comprises 
Helicobacter, Arcobacter and Wolinella. For the species C. jejuni, the focus of this 
thesis, two subspecies are recognized; C. jejuni subsp. jejuni and subsp. doylei. Little is 
known about the pathogenic role of the latter and in this thesis C. jejuni will refer to C. 
jejuni subsp. jejuni.  
 
1.1.2 Biology 
C. jejuni are curved or spiral rods that are 0.2 to 0.8 µm wide and 0.5 to 5 µm long. 
They are gram negative and do not form spores. The cells are highly motile with a polar 
flagellum at one or both ends of the cell. They are catalase and oxidase positive and 
urease negative. Temperature range for growth is 30-44°C (van Putten et al., 2009), 
with an optimum temperature of 42°C. This probably reflects an adaptation to the 
intestines of birds. C. jejuni are microaerophilic, requiring an oxygen concentration of 
3-15% and a carbon dioxide concentration of 3-5%. They have relatively small 
genomes (1.6 – 2.0 megabases) and can establish long term associations with their hosts 
(Parkhill et al., 2000). 
Figure 1.1. Electron micrograph of C. jejuni. The bacteria on the picture are the C. jejuni NCTC 11168 
strain used in this thesis (picture taken by Christina K. Johnsen, Dpt. Virology, Statens Serum Institut). 
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1.1.3 Epidemiology and typing  
C. jejuni is the most common cause of bacterial-mediated diarrhoeal disease worldwide 
and The World Health Organization (WHO) estimates that app. 1 % of the Western 
Europe population will be infected with Campylobacter each year (www.who.int). In 
several developed countries, the number of reported cases are 80 per 100 000 people 
(Friedman et al., 2000). In Denmark, 3352 cases (61 pr. 100.000) were reported in 2009 
and there has been an increasing trend of campylobacteriosis in Denmark and in most 
developed countries for the last 25 years (www.ssi.dk; Olson et al., 2008) (figure 1.2). 
Because Campylobacter enteritis rarely requires hospitalization, the number of cases is 
probably much higher (Friedman et al., 2000). This is supported by data from England 
and Whales, where it was found that for each reported case there was app. nine others 
not reported cases (Wheeler et al., 1999). In developing countries, C. jejuni is 
hyperendemic, because of poor sanitation and close human contact with animals. Here, 
infection is generally asymptomatic and diarrhoea restricted to children less than 5 years 
(Ketley, 1997). In developed countries, infection is often seasonal and targets mostly 
young adults (15-24 years) and often men are found to be susceptible (Blaser, 1997; 
Friedman, 2000). 
Figure 1.2. Registered Campylobacter, Salmonella and Yersinia patients from 1980 to 2009. The 
number of registered patients in Denmark have been increasing during the last 25 years topping in 2000-
2002.   
 
Campylobacter are found in a wide range of domestic and wild animals and 
contaminated meat or cross-contaminated food products are usually the routes of 
infection for humans. However, Campylobacter can also be acquired from contaminated 
and untreated milk, contaminated water, sausages and contact with pets, especially birds 
and cats, and international travel (Kapperud et al., 1992; Ketley, et al., 1997) (figure 
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1.3). However, approximately 50% of all infections cannot be attributed to any of the 
known risk factors, indication that other sources exist (Janssen et al., 2008). Most 
Campylobacter infections occur as aporadic cases, and outbreaks are rare. The few 
reported outbreaks are most commonly associated with raw milk or water (Engberg et 
al., 1998; Kuusi et al., 2005; Teunis et al., 2005).  
 
 
Figure 1.3. The sources of Campylobacter jejuni infection. Several sources have been found to 
contribute to the human infection but especially colonization of chicken is important. During chicken 
colonization, the C. jejuni can spread within the flocks through the feacal-oral route and obtain a high 
level of contamination within a flock. Thereby humans can be infected by consumption of untreated 
contaminated poultry products. C. jejuni is also able to enter the water supply and thereby survive and 
infect humans directly through the drinking water or via consumption of animal products, such as meat or 
milk (Young et al., 2007). 
 
Source tracking is an important issue regarding C. jejuni and human campylobacteriosis 
and good subtyping methods are needed for this. Besides source tracking, some of the 
typing methods can be very useful to study the bacterial population structure and 
evolution. Some of the earlier methods are based on phenotypic traits, such as 
biotyping, serotyping and phagetyping and are still used today. However these methods 
lack discriminatory power and also results in a large portion of untypeable strains. Since 
the 1980s there has been an increased interest in the development of molecular typing 
methods. Several techniques have been developed and have been in general use, such as 
flagellin gene (flaA) sequencing (Ayling et al., 1996), pulse field gel electrophoresis 
(PFGE) (Fujimoto et al., 1997) ribotyping (Fitzgerald et al., 1996), amplified fragment 
length polymorphism (AFLP) (Duim et al., 1999) and multilocus enzyme 
electrophoresis (MLEE) (Selander et al., 1986). flaA sequencing analyses restricted 
parts of the genome, PFGE are solely based on digestion of genomic DNA while AFLP 
includes two restriction enzymes and a primer pair and makes the method more 
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discriminatory than flaA and PFGE. MLEE analyses variations in alleles of 
housekeeping genes encoding enzymes by estimating variations in the net 
electrophoretic charges of the polypeptide. MLEE has a moderate level of 
discriminatory power but can be difficult to compare between laboratories (Riley, 
2004). Overall, none of these methods have proved high resolution, high through put 
and simple reliable and easy-to-compare data between laboratories.  
 
In extension of MLEE, multilocus sequence typing (MLST) is another molecular isolate 
characterization technique. It is based on sequencing parts of the genome and the 
method indexes variation in seven housekeeping genes (aspA, glnA, gltA, glyA, pgm, tkt, 
uncA), which evolve slowly as they are under stabilizing selection for conservation of 
metabolic function (Dingle et al., 2002). The allele fragments are approximately 
between 400 and 600 bp in length, which made them easy to sequence on the 
sequencing instruments available in the mid 1990s, when the method was developed 
(Maiden, 2006). The use of nucleotide sequence data directly accesses the variation in 
the targeted gene and the methods are more reproducible and can easily be shared 
among laboratories. The sharing is easily accessible due to a central database 
(http://pubmlst.org/) where also useful software is available.  
 
The MLST scheme was conceived as a tool for clinical microbiologists and 
epidemiologists (Urwin and Maiden, 2003) but it has also been proven very useful in 
the studies of bacterial population genetics (Smith et al., 2000; McCarthy et al., 2007; 
Sheppard et al., 2008). Studies of C. jejuni strain collections, by MLST, have confirmed 
the organisms to be genetically diverse, with a semi-clonal population structure (Dingle 
et al., 2001a, 2005). Such bacterial populations contains clusters of related organisms, 
referred to as clonal complexes and in the case of Campylobacter, these are defines as 
those isolates sharing four or more alleles with a central genotype, after which the 
complex is named (Dingle et al., 2001a). 
 
1.2 Pathogenesis of Campylobacter jejuni 
1.2.1 Clinical symptoms and complications 
Human infections are caused mainly by two species: C. jejuni and C. coli. 
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Manifestations are acute gastroenteritis, cramping abdominal pain, fever, and more 
rarely, vomiting and headaches (Allos et al., 2001). Diarrhoea often develops shortly 
after onset of abdominal pain and varies from mild, non-inflammatory, watery 
symptoms to severe and bloody. In otherwise healthy individuals, infection last for app. 
4 days with an incubation period of 1-10 days (Blaser et al., 1997). Disease outcome is 
most likely to be dependent on virulence of the infecting strain, but also host response 
and host immune status. This is suggested because patients acquiring infections abroad 
generally present clinical features of their country of origin (Ketley et al., 1997). 
 
Normally the C. jejuni infection is self-limiting but in severe cases, macrolide antibiotic 
(erythromycin) or fluoroquinolones (ciprofloxacin) is the choice of treatment (Balfour 
and Faulds, 1993). Resistances to both choices of antibiotic have been increasing among 
Campylobacter species (Engberg et al., 2001a; Gabreel and Taylor, 2006). There is 
evidence that patients infected with antibiotic-resistant strains have worse clinical 
outcomes than those infected with sensitive strains (Helms et al., 2005).    
 
Post-infectious complications can occur and Guillain-Barré Syndrome (GBS) is 
probably the most severe and well studied. It is estimated to be 1 in 1000 infections and 
causes flaccid paralysis that can affect peripheral and cranial nerves and in severe cases, 
artificial ventilation is required (Nachamkin, 2002; Kuwabara, 2007). The surface of the 
bacteria is known to be important for development of GBS because 
lipooligosaccharides (LOS) mimics the peripheral nerve gangliosides resulting in 
generation of autoreactive antibodies and thereby inflammation and tissue damage 
(Godschalk et al., 2004; Komagamine and Yuki, 2006). Miller Fisher syndrome is a 
non-paralytic variant of GBS and causes inability to move the eyes and having non-
reactive pupils (Fisher, 1956). Reactive arthritis is also associated with Campylobacter 
post-infection and a cohort study found a risk of accruing reactive arthritis to be in 
approximately 7 out of 100 cases (Hannu et al., 2002). There is a maximal interval at 4 
weeks between preceding infection and arthritis and the arthritis has a predilection for 
joints, particularly knees and ankles (Braun et al., 2000). In more rare cases C. jejuni 
has been associated with intestinal haemorrhage (Chamovitz et al., 1983), toxic 
megacolon (McKinley et al., 1980) and haemolytic uraemic syndrome (Shulman and 
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Moel, 1983). Also irritable bowel syndrome has been related to C. jejuni infection 
(Gradel et al., 2009). 
 
1.2.2 Virulence factors of Campylobacter jejuni 
C. jejuni is predicted to express several virulence factors when colonizing the intestines, 
establishing an infection and possible getting systemic. Some are more extensively 
studied than others. Below are highlighted the virulence factors important for host 
interaction and the following chapters. 
 
1.2.2.1 Motility and flagellin 
The motility of C. jejuni is important for colonization of the host by the ability of 
movement into the mucus covering the intestinal cells. C. jejuni has a polar flagellum at 
one or both ends and their cork-screw form allows them to penetrate the mucus barrier 
(Szymanski et at, 1995). For colonization, the presence of flagellin has been found to be 
essential (Wassenaar et al., 1993; Nachamkin et al., 1993). Flagellin consist of two 
subunits encoded by flaA and flaB and both are subjected to antigenic variation as well 
as phase variation (Caldwell et al., 1985; Harris et al., 1987). The flaA gene is expressed 
at much higher levels and independently of flaB, as flaA is expressed from a σ28 
promotor and flaB from a σ54 promotor (Guerry et al., 1990). Because flaA is expressed 
at a higher level, the flagellum consist normally of FlaA but both flaA and flaB have 
been found to be necessary for motility (Wassenar et al., 1993). flaA has also been 
associated with autoagglutination (AAG) where a flaA mutant failed to autoagglutinate 
(Guerry et al., 2006). Several other proteins have been found to be involved in flagellar 
expression and in the annotation of the NCTC 11168 genome, 36 open reading frames 
were assigned functions or putative functions in flagellar biosynthesis, export or 
assembly (Parkhill et al., 2000).  
 
1.2.2.2 Adherence factors 
When the bacteria have entered the mucus layer, adhesion to the epithelial cell is crucial 
for long term establishment and invasion. No single mutation completely abolishes 
binding to host cells, indicating that C. jejuni possesses multiple adhesins. Accordingly, 
several proteins have been proposed as adhesins (table 1.1).   
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Table 1.1. Overview of known adhesion factors and their importance in vitro and in vivo.   
 
Adhesin    In vitro cell line       Important for    Reference 
          host colonization in   
 
CadF  Int407  chicken              Monteville et al., 2003; Konkel et al., 1997 
FlpA  Int407  chicken             Konkel et al., 2010 
CapA  Caco-2  chicken             Ashgar et al., 2007 
JlpA  HEp-2  no             Jin et al., 2001, Flanagan et al., 2009 
PEB1  HeLa  mouse             Kervella et al., 1993, Pei et al., 1998 
PEB4 (surA) Int407  mouse             Asakura et al., 2007 
Cj1496c  Int407  chicken             Kakuda and DiRita, 2006  
MOMP   Int407  ND             Moser et al., 1997 
CPS  Int407  ferret, chicken            Bacon et al., 2001, Jones et al., 2004 
LOS  Int407, Caco2 chicken, mouse               Fry et al., 2000, Müller et al., 2007,  
                 Naito et al., 2010  
CadF: Campylobacter adhesion to fibronectin, FlpA: fibronectin-like protein A, CapA: Campylobacter 
adhesion protein A, JlpA: jejuni lipoprotein A, PEB1 and 4: protein Pei, Ellison and Blaser 1 and 4, 
MOMP: Major outer membrane protein, CPS: Capsular polysaccharide, LOS: Lipooligosaccharide, ND: 
Not determined 
 
Fibronectin (Fn) is a eukaryotic molecule part of the extracellular matrix (ECM), which 
serves as binding component for C. jejuni (figure 1.4). CadF (Campylobacter adhesion 
to fibronectin) and FlpA (fibronectin-like protein A) are identified as fibronectin-
binding proteins, important for adhesion to epithelial cells in vitro and chicken 
colonization (Flanagan et al., 2009).  
Figure 1.4. C. jejuni binding to an extracellular matrix (ECM) component (M. Konkel).  
 
C. jejuni has two putative autotransporters, CapA and CapB (Campylobacter adhesion 
protein A and B), where CapA has been found important for in vitro adhesion and 
chicken colonization (Ashgar et al., 2007). Autotransporters represent, in other 
pathogens, an extensive and rapidly growing family of secreted virulence-associated 
proteins (van Putten et al., 2009). JlpA (jejuni lipoprotein A) is another characterized 
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adhesin, crucial for HEp-2 cell binding (Jin et al., 2001). It is a surface exposed 
lipoprotein that binds to Hsp90-alpha, localized on the surface of HEp-2 cells. The 
binding activates NF-қB and p38 mitogen-activated protein (MAP) kinase, both of 
which contribute to proinflammatory responses (Jin et al., 2003). The PEB1 and 4 
adhesins are paradoxically located in the periplasma but found important for adherence 
to epithelial cells (Kervella et al., 1993; Pei et al., 1998) and for biofilm formation 
(PEB4) (Rathbun and Thomson, 2009). Another periplasmic protein, important for 
adhesion, is the glycoprotein Cj1496c. It has homology to a magnesium transporter and 
has been shown to be important for adhesion and invasion to human epithelial cells and 
for chicken colonization (Kakuda and DiRita, 2006). The 46-kDa pore-forming major 
outer membrane protein (MOMP), encoded by the porA gene  (Schroder & Moser, 
1997) has a hyper variable surface exposure between isolates, probably due to selective 
pressure by the immune system (Clark et al., 2007). Lipooligosaccharides (LOS) 
comprises two main components: a hydrophobic lipid A anchor and an oligosaccharide 
consisting of a conserved inner core and a variable outer core (Golec, 2007). It has 
previously been shown to be implicated in adherence, invasion and colonization (Fry et 
al., 2000; Naito et al., 2010). It is highly variable and therefore plays a crucial role in 
immune avoidance and found to be important for serum resistance (Guerry et al., 2000). 
Various LOS structures resemble human neuronal gangliosides and this molecular 
mimicry is thought to lead to the autoimmune disorders, Guillain-Barré and Miller 
Fisher syndrome (Guerry et al., 2002). The capsule was until recently thought to be a 
high molecular weight lipopolysaccharide, but is now known to be a highly variable 
capsular polysaccharide (Karlyshev et al., 2000). The C. jejuni capsule is important for 
adherence and invasion of epithelial cells, chicken colonization and serum resistance 
(Bacon et al., 2001; Jones et al., 2004; Bachtiar et al., 2007). I addition to LOS and 
capsule, C. jejuni may produce another type of polysaccharide. Its biosynthesis might 
require carbamylphosphate and it is possibly involved in biofilm formation (Kalmokoff 
et al., 2006; McLennan et al., 2008). The C. jejuni binding to epithelial cells is 
illustrated at figure 1.5. 
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Figure 1.5. C. jejuni binding to epithelial cells. Left immunofluorescence image showing C. jejuni 
binding to a INT407 cell and right a scanning electron microscopy image showing C. jejuni binding to 
Caco-2 cells (M. Konkel). 
 
1.2.2.3 Invasion  
Early studies of intestinal biopsies and in vitro studies of C. jejuni showed that the 
bacterium is able to invade gut tissue cells (van Spreeuwel et al., 1985; Oelschlaeger et 
al., 1993; Ketley, 1997) and since then, numerous in vivo and in vitro studies have 
provided information on the invasion level and mechanisms behind the invasion 
process. However, still little is known about the mechanisms by which it enters the host 
cells.  
 
The entrance of the bacteria is mediated through disrupted tight junctions of epithelial 
cells (Bras et al., 1999; MacCallum et al., 2005; Chen et al., 2006). Subsequently it gets 
through the epithelial cell barrier either via transcellular or paracellular movements. The 
latter allows the bacterium to move to the basolateral surface and there either reinvade 
the epithelial cell or be taken up by macrophages where C. jejuni is able to replicate and 
induce apoptosis (Kielbauch et al., 1985; Hickey et al., 2005). After internalization into 
intestinal epithelial cells, C. jejuni resides within a membrane bound compartment  and 
over time acquires a metabolic state that renders it unculturable under standard culture 
(Kielbauch et al., 1985; Humphrey et al., 1986; Russel et al., 1994). A study by Watson 
and Galan (2008) showed that this state could be interrupted by conditions of severe 
oxygen limitation, suggesting that when C. jejuni enters the epithelial cells it either 
becomes oxygen sensitive or alter its respiration mode (Watson and Galan, 2008). The 
nucleotide sequence of the genome of the C. jejuni 81-176 has further revealed genes 
involved in additional respiratory pathways and these could contribute to the ability of 
surviving within epithelial cells (Hofreuter et al., 2006). C. jejuni invasion has also been 
related with the ability to stimulate MAP kinases, leading to the production of the pro-
inflammatory cytokine, IL-8 (Hickey et al., 2000; Watson and Galan, 2005).  
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Upon contact with epithelial cells, C. jejuni secretes a set of proteins termed 
Campylobacter invasive proteins (Cia proteins) and at least one of them (CiaB, a 73 
kDa protein) has been shown to be crucial for internalization (Konkel and Cieplak Jr, 
1992; Konkel et al., 1999). CiaB proteins are also found to be secreted in the presence 
of chicken serum and mucus (Biswas et al., 2007). The secretion is not mediated by a 
classical type III secretion system but utilizes instead the flagellum as a type III like 
secretion system (Konkel et al., 2004).  
 
1.2.2.4 Other factors important for host interaction 
A number of other virulence factors and survival mechanisms have been identified in C. 
jejuni, the ones relevant for the following chapters are mentioned below. 
 
Genetic variation and natural transformation 
Genetic variation is important to consider while working with or developing new typing 
methods. C. jejuni displays extensive genetic variation caused by intragenomic 
mechanisms, such as phase variation, gene duplication, deletion, frameshifts and point 
mutations (Young et al., 2007). Also genetic exchange between strains contributes to 
the genetic variance and because C. jejuni is naturally competent, it can take up DNA 
from the environment, which leads to recombination between strains and allows the 
generation of more genetic diversity (de Boer et al., 2002). Genes required for natural 
transformation have been identified as components of type II secretion system (Avrain 
et al., 2004). Also a plasmid-encoded type IV secretion system as well as genes for N-
linked glycosylation, LOS biosynthesis has been shown to be implicated in natural 
transformation (Bacon et al., 2000; Fry et al., 2000; Larsen et al., 2004).  
 
Biofilm formation and quorum sensing 
The formation of biofilm is a well-known bacterial way of growth that increases the 
ability of bacteria to survive in extreme conditions such as UV radiation, predation and 
desiccation (Elasri et al., 1999; Matz et al., 2005). The bacteria in biofilms also become 
more resistant to disinfectants and antimicrobials compared to their planktonic 
counterparts (Fux et al., 2005). Several studies have shown that C. jejuni is capable of 
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forming biofilm and it is hypothesised to play a role in the dispersal of the bacteria in 
poultry farms through the water supply (Lehtola et al., 2006). Recent studies have 
shown that C. jejuni biofilm formation is enhanced during aerobic conditions suggesting 
that the bacteria are well adapted for survival in the environment in a biofilm (Reuter et 
al., 2010). The molecular details regarding C. jejuni biofilm are still deficient but there 
is evidence that the flagellum is important, because a flaB mutant has showed reduced 
biofilm formation (Reeser et al., 2007) and flagellar modification (Cj1337) mutants do 
not adhere to glass surfaces (Joshua et al., 2006).  
 
Quorum sensing (QS) is a cell-to-cell communication system that involves the 
synthesis, secretion and detection of extracellular signalling molecules termed 
autoinducers. C. jejuni do, as most pathogens, produce the signal inducer 2 (AI-2) that 
is a collection of interchangeable molecules synthesised by a key enzyme, LuxS 
(Schauder et al., 2001). AI-2 production has been associated with regulation of biofilm 
formation (Reeser et al., 2007), autoagglutination (Jeon et al., 2003; Guerry et al., 
2006), swarming motility (Jeon et al., 2003), transcription of cytolethal discending toxin 
(CDT)  (Jeon et al., 2005), colonization of chickens (Quinones et al., 2009) and 
sensitivity to hydrogen peroxide (He et al., 2008). AI-2 activity has further been 
demonstrated in several foods, such as milk, apple juice and chicken broth, suggesting 
an adaptation to the environment (Cloak et al., 2002).  
 
Cytolethal distending toxin and haemolysin 
C. jejuni secretes a toxin termed cytolethal distending toxin (CDT) and is a complex of 
CdtA, CdtB and CdtC. The three subunits act together to block cell division by 
performing cell cycle arrest (Lara-Tejero and Galan, 2001). CdtA and CdtC bind to the 
cell surface helping to deliver the active subunit CdtB, which uses its DNase-I-like 
activity to cleave dsDNA molecules during the G1 and G2 phase (Whitehouse et al., 
1998). CDT is expressed in the bacteria in the colonization of their natural host, 
chicken, but the chickens do not generate CDT-neutralizing antibodies (AbuOun et al., 
2005). The toxin might provide a way to either avoid host immune-response 
mechanisms or redirect them towards tolerance (Young et al., 2007). 
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Haemolysis is the breakage of the red blood cell membrane, causing the release of 
haemoglobin and other internal components. It is a strategy employed by some bacteria 
to liberate heme for use as iron source (Stintzi et al., 2008). Haemolysins are associated 
with virulence in several bacterial pathogens and some studies have reported haemolytic 
activity of C. jejuni (and C. coli) (Arimi et al., 1990; Misawa et al., 1995). Two genes 
have been associated with haemolytic activity in C. jejuni: ceuE and pldA. The CeuE 
protein is a lipoprotein that functions as a periplasmic binding protein. It is a part of an 
ABC transport system associated with enterobactin transport across the inner membrane 
(Stintzi et al., 2008). pldA, encoding phospholipase A, has been studied for C. coli and 
found to contribute to cell-associated haemolysis (Grant et al., 1997). A pldA 
homologue is present in the genome of C. jejuni NCTC 11168 (Parkhill et al., 2000). A 
putative haemolysin tlyA (Cj0588) is also present in NCTC 11168 but the activity has 
not been proved (Coote et al., 2007). 
 
1.3 Experimental Campylobacter infection models 
The biological significance of the relatively large number of identified virulence factors 
still remains unknown. This is mainly because of the lack of suitable infection models. 
However, the wide diversity of factors that most likely interact to produce disease after 
infection with C. jejuni makes it difficult to find or develop a good animal model. Data 
suggest that the disease outcome depends on several factors, such as the dose, genetics, 
innate and adaptive immune status, the enteric microflora and number of repeat 
challenges (Blaser et al., 1997; Oberhelman et al., 2003; Pazzaglia et al., 1991). A good 
animal model can be defined as one easy to handle and accessible to the majority of 
research laboratories, it should be relatively inexpensive and must be reproducible.  
 
Mice provide a convenient model for the study of several pathogenic bacteria, but mice 
with normal flora and immune system are usually not susceptible to infection with C. 
jejuni. Mice can be transiently colonized, but the model lack robustness for colonization 
or pathogenesis studies (Young et al., 2000). Mice with a defined limited gut flora have 
shown promising results for the study of C. jejuni pathogenesis. The model leads to 
reproducible colonization at high levels, resulting in mild inflammation of large 
intestine followed by clearance after several weeks. SCID mice with limited gut flora, 
 20 
in contrast, remain colonized at high levels, with tissue inflammation (Chang and 
Miller, 2006). Another mice model for colonization is a MyD88 mouse deficient in the 
adapter protein myeloid differentiation factor 88, required for signalling through most 
TLRs (Watson et al., 2007). Mice deficient for IL-10 have been infected with as little as 
106 CFU C. jejuni NCTC 11168, which produce significant disease and pathological 
lesions similar to responses seen in humans (Mansfield et al., 2007)    
 
Avian models are reproducible and have also been used widely (Biswas et al., 2006; 
Hendrixson and DiRita, 2004; Jones et al., 2004; Ringoir et al., 2007) but the bacteria 
rarely cause disease and therefore is the model more suitable to study colonization and 
not virulence and therefore limited in terms of understanding the mechanism of enteric 
infection (Dorrell and Wren, 2007). Other models that have been used are ferrets (Bell 
and Manning, 1990), hamsters (Humphrey et al., 1985, 1986), dogs (Olson and 
Sandsteds, 1987), rabbits (Caldwell et al., 1983, Pavlovskis et al., 1991) and pigs (Hu 
and Kopecko, 2000; Law et al., 2009). The animal model most similar to human 
infection is the oral infection of non-human primates. C. jejuni causes acute 
enterocolitis in infected macaques and the clinical symptoms resembles the infection 
observed in humans (Islam et al., 2006; Russel et al., 1989). However this model is 
rarely used, probably due to economical and ethical reasons.    
 
Progress has also been made in the use of ex vivo organ culture model for both human 
and chicken intestinal biopsies (Grant et al., 2006; Byrne et al., 2007). These assays 
enable the maintenance of intestinal mucosal tissue samples and the study of both host-
pathogen interactions and host-immune responses (MacCallum et al., 2006; Byrne et al., 
2007).   
 
1.4 Immune response to Campylobacter jejuni infection  
Several mechanisms of the innate immune system are involved in the control of C. 
jejuni, including the complement system, and phagocytic activity of macrophages. 
Humoral immunity also plays an important role in the response against the bacterium.  
 
The innate immune response is a key determinant of subsequent adaptive immune 
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activation and outcome of infection (Boyd et al., 2007). Innate immunity is initiated by 
the bacterial contact to the intestinal epithelial cells where host pattern recognition 
receptors (PRRs), on the surface of intestinal epithelial cells, can respond directly to a 
pathogen or a pathogen component (pathogen-associated molecular patters) (Eckmann, 
2005). The recognition triggers host signal transduction pathways and the transcription 
of genes encoding proinflammatory molecules (O´Hara and Shanahan, 2006). The most 
extensively studied PRRs are the Toll-like receptors (TLRs). The TLR family is a 
highly conserved group of molecules that play a role in pathogen detection and 
initiation and regulation of immune responses. Toll-like receptor 5 (TLR5) is found on 
the apical surface of intestinal epithelial cells. It recognizes conserved epitopes within 
some bacterial flagellins and initiates signalling that leads to the expression of the gene 
encoding the chemokine interleukin-8 (IL-8). Studies of C. jejuni have demonstrated 
secretion of IL-8 in response to wild type C. jejuni but it is unclear whether TLR5 is 
involved in the stimulation or if C. jejuni has evolved specific adaptations (Hickey et 
al., 2000; Watson and Galan, 2005). The release of IL-8, and other proinflammatory 
molecules, activates innate immune defence, such as dendritic cells (DS) and promotes 
acquired immune responses (Fleckenstein and Kopecko, 2001) (figure 1.6). DCs play 
important roles in both the innate and adaptive immune response to microbial 
pathogens. They are the major antigen-presenting cells and are widely distributed in 
tissues including the intestinal mucosa (Medzhitov and Janeway, 1997). DCs regulate 
the type of T-cell mediated immune response to an offending agent and are also a 
source of proinflammatory cytokines. Further they are the only cells that are able to 
initiate proliferation in naïve T cells thereby inducing the primary immune response and 
permitting the establishment of immunological memory (Palucka and Banchereau, 
2002). For C. jejuni it was recently found that it readily was internalized in DCs over a 
2 hr period but after prolonged incubation period (24 hr or 48 hr) only a few viable 
intracellular bacteria remained (Hu et al., 2006). Further, C. jejuni induced the 
maturation of the DCs as indicated by up-regulation of cell surface marker proteins, 
stimulation of interleukins and activation of NF-қβ (figure 1.5). When stimulation was 
made with heat killed C. jejuni cells, a minor reduction in cytokine production was 
observed and a major stimulant was found to be the LOS of the C. jejuni cells surface 
(Hu et al., 2006). Another important effecter molecule is the antimicrobial β-defensin. It 
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is a family of epithelial antimicrobial peptides and also a major component of host 
innate defence at the gastrointestinal mucosal surface. These have also found to play an 
important role against C. jejuni (Zilbauer et al., 2005) 
 
 
Figure 1.6. Innate immune response to C. jejuni infection in humans. C. jejuni evade the mucus layer 
and binds to, and is internalized by, the epithelial cells. This causes interleukin (IL)-8 production that 
recruits the dendritic cells, macrophages and neutrophils, which interact with C. jejuni. These interactions 
result in a pro-inflammatory response and increase in the corresponding cytokines (Young et al., 2007. 
Modified). 
 
During the infectious process of C. jejuni, most people develop humoral responses to a 
number of antigens. It has previously been suggested that only a few protein antigens 
are important in the induction of protective immunity against Campylobacter infections 
(Newell and Nachamkin, 1992). Though, more recent studies have shown that serum 
antibodies in endemically exposed individuals were directed against a wide range of 
antigens (Cawthraw et al., 2000). In human, circulation antibodies are first detectable 6 
to 7 days after the onset of illness and rise rapidly shortly afterwards (Newell and 
Nachamkin, 1992). Immunoglobulin (Ig) A levels peak 7 to 10 days after onset of 
symptoms and decline rapidly after onset of illness. IgG levels peak after 3 to 4 weeks 
and remain high for a longer time. There is an active secretion mechanism for IgM at 
mucosal surfaces and IgM levels remains longer than IgA but shorter than IgG (Blaser 
and Duncan, 1984; Strid et al., 2001; Cawthraw et al., 2002).  
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1.5 Vaccines against Campylobacter jejuni 
Until today, no vaccine against C. jejuni is available but several attempts have been 
made so far and still more are coming. Vaccinations against C. jejuni are targeted either  
towards poultry or humans. A vaccine used in poultry production would lead to a 
reduction or elimination of C. jejuni in the animals and thereby reduce the 
contamination of meat and infections in humans. Vaccination of humans would 
probably not be of interest for the main population but a have a huge importance for 
immunocompromised patients or travellers.  
  
In Salmonella typhi and Vibrio cholera, live attenuated oral vaccines, have provided 
good protection in field or volunteer challenge studies (Black et al., 1990; Kaper et al., 
1984) and could be an attractive approach for C. jejuni as well. On the other hand, 
paucity of information on pathogenecity and physiology of C. jejuni complicates it. 
Additionally, a study has showed that viable non-colonizing strain of C. jejuni failed to 
initiate a protective immunity in chickens (Ziprin et al., 2002). Another important 
subject is the association of the neuropathy and autoimmune disease Guillain-Barré 
syndrome with C. jejuni infections which make the development of whole cell vaccines 
problematic. Lipo-oligosaccharide from the C. jejuni cell wall contains ganglioside-like 
structures which induces, when injected in rabbits, the antibody cross reaction know to 
cause neuropathy that resembles acute motor axonal neuropathy (Hughes and 
Cornblath, 2005).  
 
Killed whole cells used as vaccines have several advantages because they are natural 
occurring microparticles and could improve interactions between their surface and 
mucosal lymphoid tissue (Baqar et al., 1995). They are also inexpensive to produce and 
contain multiple possible protective antigens. A study demonstrated limited protection 
in ferrets after oral vaccination with C. jejuni killed cells (Burr et al., 2005). Subunits or 
isolated proteins from C. jejuni or purified proteins from the bacterial surface are 
another strategy in vaccine development. Several antigens have been suggested as 
vaccine candidate. Flagellin is known as immunodominant antigen recognised during 
infection and therefore has been suggested as vaccine candidate in several studies 
(Martin et al., 1989; Wenman et al., 1985). Though, the antigenic diversity and the 
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glycosylation of Campylobacter flagellin make the vaccine development problematic 
(Scott, 1997). The adhesion factor, PEB1, is a highly immunogenic protein, but despite 
this, a study demonstrates that significant levels of anti-PEB serum IgG did not protect 
against C. jejuni after oral challenge (Sizemore et al., 2005). MOMP has in its native 
form been found suitable for vaccine design (Zhang et al., 2000; Huang et al., 2007).   
 
Despite more than 10 years of research, the knowledge concerning protective 
Campylobacter antigens is still incomplete. The choice of antigen is a critical point for 
effective vaccine construction and development of comparative proteomics and/or the 
analysis of C. jejuni metabolic diversity will hopefully facilitate their identification 
(Jagusztyn-Krynicka et al., 2009). 
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2. Material and methods 
2.1 Overview of material and methods 
In figure 2.1 below are the material and methods used in this thesis. They are outlined in 
details in the following chapters.  
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Figure 2.1. Schematic outline of the PhD study. The main material, methods and results are presented 
in the flow chart. Left and down is a MLST study with clinical isolates. The study is described in details 
in chapter 3, paper 1 (appendix 2). The two studies outlined in the middle and down both have an open 
reading frame library as main material with different screen assays. The studies are described in details in 
chapter 4 and 5, manuscript 1 and 2. The last study, shown at the right and down present a fibronectin 
binding protein and fibronectin binding assays and is described in details in chapter 6, manuscript 3.   
 
 26 
2.1 List of paper and manuscripts 
Paper 1 (chapter 3, appendix 2):  
MLST clustering of Campylobacter jejuni isolates from Patients with 
Gastroenteritis, Reactive arthritis and Guillain-Barré Syndrome. 
Lene N. Nielsen1,2, Samuel S. Sheppard3, Noel D. McCarthy3; Martin C. Maiden3, Hanne Ingmer2, Karen 
A. Krogfelt1  1 Statens Serum Institut, Department of Microbial Surveilliance and Rescearch, 
Copenhagen, Denmark. 2 Department for Veterinary Disease Biology, Faculty of life Sciences, 
University of Copenhagen, Denmark. 3 Department of Zoology, University of Oxford, United Kingdom.  
Published in: Journal of Applied Microbiology 108 (2010) 591–599. 
 
Manuscript 2 (chapter 4):  
Identification of immunogenic and virulence associated Campylobacter jejuni 
proteins. 
Lene N. Nielsen1,2, Thomas Luijkx3, Christina S. Vegge2, Christina Kofoed Johnsen1, Peit Nuijten3, 
Karen A. Krogfelt1, Hanne Ingmer2. 1 Statens Serum Institut, Department of Microbiological and 
Surveillance and Research, Copenhagen, Denmark. 2 University of Copenhagen, Department of 
Veterinary Disease Biology, Copenhagen, Denmark. 3 Merck, Nobilon International B.V., Boxmeer, The 
Netherlands.  
In preparation 
 
Manuscript 3 (chapter 5):  
Screening for virulence associated phenotypes of Campylobacter jejuni. 
Lene N. Nielsen1,2, Christina S. Vegge2, Kirstine A. Frandsen1, Kaare V. Grunddal1, Mads P. Jensen1, 
Hanne Ingmer2, Karen A. Krogfelt1. 
1 Statens Serum Institut, Department of Microbiological and Surveillance and Research, Copenhagen, 
Denmark, 2 University of Copenhagen, Department of Veterinary Disease Biology, Copenhagen. 
Ongoing work 
 
Manuscript 4 (chapter 6):  
Identification of a fibronectin binding protein of Campylobacter jejuni 
Lene N. Nielsen1,2, Christina S. Vegge2, Karen A. Krogfelt1, Hanne Ingmer2, Michael Konkel3 
1 Statens Serum Institut, Department of Microbiological and Surveillance and Research, Copenhagen, 
Denmark, 2 University of Copenhagen, Department of Veterinary Disease Biology, Copenhagen, 
Denmark, 3 Washington State University, School of Molecular Biosciences, Pullman, Washington, 
United States of America. 
In preparation 
 
 
 
 
 
 27 
3. MLST clustering of Campylobacter jejuni isolates from 
patients with gastroenteritis, reactive arthritis and Guillain-
Barré Syndrome  
 
3.1 Abstract  
Aims: To determine the diversity and population structure of Campylobacter jejuni (C. 
jejuni) isolates from Danish patients and examine the association between MLST types 
and different clinical symptoms including gastroenteritis (GI), Guillain-Barré Syndrome 
(GBS) and reactive arthritis (RA). Methods and Results: Multilocus sequence typing 
(MLST) was used to characterize 122 isolates, including 18 from patients with RA and 
8 from patients with GBS. The GI and RA isolates were collected in Denmark in 2002-
2003 and the GBS isolates were obtained from other countries. In overall, 51 sequence 
types (STs) were identified within 18 clonal complexes (CCs). Of these three CCs, ST-
21, ST-45 and ST-22 clonal complexes accounted for 64 percent of all isolates. The 
GBS isolates in this study significantly grouped into the ST-22 clonal complex, 
consistent with the PubMLST database isolates. There was no significant clustering of 
the RA isolates.  
Conclusions: Isolates from Denmark were found to be highly genetic diverse. GBS 
isolates grouped significantly with clonal complex ST-22 but the absence of clustering 
of RA isolates indicated that the phylogenetic background for this sequela could not be 
reconstructed using variation in MLST loci. Possibly, putative RA-associated genes 
may vary, by recombination or expression differences, independent of MLST loci. 
Significance and Impact of the Study: MLST typing of C. jejuni isolates from Danish 
patients with gastroenteritis confirmed that the diversity of clones in Denmark is 
comparable to that in other European countries. Furthermore, a verification of the 
grouping of GBS isolates compared to RA isolates provides information about 
evolution of the bacterial population resulting in this important sequela.  
 
3.2 Introduction 
Campylobacter jejuni is the leading bacterial cause of gastroenteritis in the 
industrialized world causing almost 500 million annual cases worldwide (Friedman et 
al., 2000). In Denmark, the prevalence of campylobacteriosis was 71 cases per 100.000 
in 2007 (www.ssi.dk). The number of laboratory-confirmed cases has increased in 
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Denmark over a 10-year period from 2665 cases in 1997 to 3868 cases in 2007 and 
currently accounts for more than twice of notifications of Salmonella, consistent with 
other developed countries. Most Campylobacter infections are sporadic and several risk 
factors have been identified including consumption of raw milk or contaminated water, 
red meat and poultry, contact with pets (especially birds and cats), and international 
travel (Kapperud et al., 1992). 
 
The symptoms of campylobacteriosis vary from diarrhoea to severe invasive disease 
and sequelae including Guillain-Barré syndrome (GBS), a demyelinating disorder 
resulting in acute muscular paralysis. Affected people develop weakness of the limbs 
and the respiratory muscles and areflexia (Nachamkin et al., 1998). Approximately one 
case of GBS occurs for every 1,000 cases of campylobacteriosis and of these, 20 % are 
left with some disablement, sometimes needing mechanical ventilation. Approximately 
2 to 3 % of cases result in death with many more occurring in the developing world 
(Willison and O´Hanlon, 2000). GBS is believed to be a result of molecular mimicry of 
lipoologosaccharide, a part of C. jejunis cell envelope, and sugar moieties on nerve 
gangliosides. Antibodies raised during Campylobacter infection containing such 
ganglioside mimics, can cross-react with gangliosides in the patients and lead to 
demyelinization of nerves and degeneration of axons (Nachamkin et al., 1999; Ang et 
al., 2004). 
 
Campylobacteriosis is also associated with another immune-mediated sequela, reactive 
arthritis (RA), a reactive arthropathy. It occurs in between 0.6% and 24% of the patients 
(Pope et al., 2007). Multiple joints can be affected, in particular the knee joint, with 
symptoms of pain and incapacitation usually resolving completely within several 
months (Jansen et al., 2002).  
 
Discriminatory typing methods to study the population genetics of C. jejuni isolates are 
crucial to improve our understanding of the epidemiology and genetic background of 
this pathogen. Multilocus sequence typing (MLST) has proved to be a valuable typing 
tool for discriminating Campylobacter isolates and defining population structure 
(Dingle et al., 2001a). MLST is based upon an allelic profile obtained by sequence 
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analysis of seven housekeeping genes. The allelic profile is summarized by a sequence 
type assigned using an online database (PubMLST). Relatedness can be inferred and 
isolates can be grouped as clonal complexes. The advantages of MLST, compared to 
other molecular methods, such as pulse-field gel electrophoresis, are standardized 
nomenclature, free access to the database and direct comparability of results between 
different studies/laboratories.   
      
Previous studies have shown that certain genotypes are more common cause of disease 
in humans while others may be less important (Manning et al. 2003; Siemer et al., 2004, 
Sheppard et al., 2009a and b). In this study, the genetic diversity among isolates from 
human disease in Denmark was investigated and the relationship between Sequence 
Types (STs) and Clonal Complexes (CCs) and different clinical symptoms of the 
patients was determined.  
 
3.3 Material and Methods 
3.3.1 Strain collection 
During the period 2002-2003 consecutive faecal isolates were obtained in the diagnostic 
laboratory at SSI. On a follow up study for sequelae cases of human gastroenteritis (n = 
96), reactive arthritis (n = 18) and GBS (n=0) were defined (Schiellerup et al. 2008). 
Since no GBS cases were detected during the investigation, 8 previously described GBS 
isolates originated from China, Japan and Mexico were included in the study (Engberg 
et al., 2001; Nachamkin et al., 2002; Leonard et al., 2004). In the phylogeny analysis, 
additional GBS MLST types were further extracted from the MLST database 
(PubMLST).  
 
3.3.2 Bacterial growth and preparation of chromosomal DNA 
The isolates were cultured on Campylobacter blood free medium (mCCDA) agar plates 
(SSI, LAB112) and subsequently grown on blood agar plates with 5 % yeast for 24-48 
hours at 37°C under microaerophilic conditions. For isolation of chromosomal DNA, a 
suspension of C. jejuni cells was prepared in 250 µl PBS in a 0.5 ml eppendorf tube. 
The suspension was vortexed briefly, heated at 100°C for 10 min and centrifuged at 
13,000 rpm for 10 min. The supernatant was removed and stored at -20°C until it was 
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required for PCR amplification. 
 
3.3.3 PCR amplification and sequencing  
Internal fragments of seven gene targets (aspA; glnA; gltA; glyA; pgm; tkt; uncA) were 
amplified by PCR with primers stated at the MLST database (PubMLST). The 
amplification reaction mixture comprised ~ 10 ng campylobacter chromosomal DNA, 1 
µM each PCR primer, 1X PCR buffer, 1.5 mM MgCl2, 0.8 mM  deoxynucleoside 
triphosphates and 1.25 U of Amplitaq polymerase. Reaction conditions: 95°C for 3 min, 
35 cycles of 94°C for 20 sec, annealing temperature for each primer set at 50°C for 20 
sec, and extension at 72°C for 1 min, with a final extension step for 5 min. PCR product 
was confirmed by agarose gel electrophoresis. PCR products were purified by 
precipitation with 20% polyethylene glycol-2.5 M NaCl and their nucleotide sequences 
were determined on each strand with BigDye Reaction mix in accordance with the 
manufacturers’ instructions.  
 
3.3.4 Allele and ST assignment 
Sequences were commercially determined on both DNA strands and assembled from 
resultant chromatograms using the Staden suite of computer programs (Staden, 1996). 
Consensus sequences for each allele were assigned an allele number and the 7-locus 
(3309bp) ST by interrogation of the Campylobacter MLST database (http://pubmlst.org/ 
campylobacter/). Novel alleles and STs were submitted to the MLST database to obtain 
new numbers.  
 
3.3.5 Phylogeny analysis 
7-locus allelic profiles were concatenated and used to construct genealogies using two 
methods for infering evolutionary relationships among C. jejuni STs. First relatedness 
of isolates was represented by a dendrogram constructed by cluster analysis using the 
unweighted pair group method with arithmetic mean (UPGMA) in the program 
START2, available at www.pubmlst.org (Jolley et al., 2001). The second phylogenetic 
analysis estimated the clonal genealogy of STs using the model-based approach to 
determining bacterial microevolution: CLONALFRAME (Didelot and Falush, 2007). This 
is a model that calculates clonal relationships with improved accuracy as it distinguishes 
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point mutations from imported chromosomal recombination events – the source of the 
majority of allelic polymorphisms. Analysis was carried out on concatenated sequences 
representing 51 STs, from 122 isolates from RA, GBS, and GI. The program was run 
with 50,000 burnin followed by 50.000 subsequent iterations. The consensus trees 
represent combined data from three independent runs with 50% majority rule consensus 
required for inference of relatedness. 
 
Because of statistical limitations, we included and compared the typed GBS isolates 
with the GBS isolates in the PubMLST database which are distributed with the 
complexes ST-22 (30.5%), ST-21 (16.5%), ST-403 (8%), ST-508, 61 and 42 (5.5%), 
ST-48, 658, 52, 362, 607 and 206 (2.7%) and isolates currently unassigned to a lineage 
with 11% (http://www.mlst.net).  
 
3.3.6 Statistical analysis 
Association between the clonal complex and the clinical diagnosis was assessed by 
Fisher´s exact test (also known as the Fisher-Freeman-Halton test) using software SAS 
(Sas Institute, 2008) Counts from the rare CCs were grouped into category Other.  
 
3.4 Results 
3.4.1 Diversity of sequence types (ST) and clonal complexes (CC)  
Among the 122 isolates, 51 STs clustering in 18 clonal complexes were identified. 
Three clonal complexes; ST-21, ST-45 and ST-22, predominated and accounted for 
nearly 64% (78/122). In the ST-21 complex, ST-388 and ST-53 were the most common 
sequence types each representing 6.6%. The ST-45 complex, the second most common 
group, was dominated by ST-45 with 13.9%. The ST-22 complex represented only two 
groups, ST-22 and ST-567, with the ST-22 as main sequence type with 9.9%. Despite 
the fact that the ST-21 complex was the most frequent group, the subgroup ST-45 in 
ST-45 complex was found to be the most common, accounting for 17 out of 122 
isolates. A number of isolates were found in CCs only represented by one or two STs 
(table 3.1).   
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Table 3.1. Sequence types and clonal complexes among 122 human isolates grouped as clinical disease 
and results in parenthesis from Fishers exact test (p=0.0022) for the most frequent CCs (21, 22, 42 and 
48). For CCs with more than one isolate, the accumulated value is shown in the row for the last isolate. 
Isolate number asp gln glt gly pgm tkt unc STa CCb diagn 
ST freq. 
(FE) 
1575, 1576, 1580, 1581  1 3 6 4 3 3 3 22 22 GBS 4  
1577 1 3 6 4 3 3 1 567 22 GBS 1 (0.918) 
1579, 1582 1 2 42 4 256 9 8 1672 42 GBS 2 (0.33) 
1578 8 10 16 2 11 12 6 2049 354 GBS 1 (1.90) 
1319 7 1 52 83 2 3 6 3708 UNc RA 1 
1372 33 160 30 79 19 62 5 3614 UN RA 1 
1209 33 160 30 79 104 62 5 UN UN RA 1 
1152, 1336 2 1 1 3 2 1 5 21 21 RA 2 
1142, 1149, 1172 2 1 21 3 2 1 5 53 21 RA 3 (5.61) 
1015, 1313 1 3 6 4 3 3 3 22 22 RA 2 (2.06) 
1092, 1231 4 7 10 4 1 7 1 45 45 RA 2 
1037 4 7 10 4 42 7 1 137 45 RA 1 
1014, 1046  4 7 10 10 2 3 1 2589 45 RA 2 (4.13) 
1093, 1094 2 4 1 2 19 62 5 2955 48 RA 2 (1.18) 
1312 1 4 2 2 6 3 1 219 61 RA 1 
1515 2 1 12 121 2 1 5 3709 UN GI 1 
1417, 1418, 1566 2 1 1 3 2 1 5 21 21 GI 3 
1535, 1551 2 1 12 6 2 1 5 24 21 GI 2 
1540, 1542 8 1 6 3 2 1 1 44 21 GI 2 
1032, 1525, 1567, 1571 2 1 12 3 2 1 5 50 21 GI 4 
1526, 1543, 1544, 1545, 1548 2 1 21 3 2 1 5 53 21 GI 5 
1058, 1530, 1550 2 1 5 2 2 1 5 251 21 GI 3 
1025, 1076, 1416, 1422*  43 1 1 3 2 1 5 388 21 GI 8 
1517 2 1 5 3 3 1 5 815 21 GI 1 
1506 2 7 12 3 2 1 5 1461 21 GI 1 
1520 2 1 1 4 1 62 5 1820 21 GI 1 
1516 2 1 177 3 2 1 5 1823 21 GI 1 
1565 2 1 4 3 2 1 5 2057 21 GI 1 (29.9) 
1047, 1049, 1084, 1528, 1564, 1574 1 3 6 4 3 3 3 22 22 GI 6 
1519 1 2 42 4 3 3 3 2615 22 GI 1 (11.02) 
1023, 1533, 1539 1 2 3 4 5 9 3 42 42 GI 3 (3.93) 
1006, 1091, 1507, 1508, 1510**  4 7 10 4 1 7 1 45 45 GI 15 
1028, 1531, 1532 4 7 10 4 42 7 1 137 45 GI 4 
1509, 1511 4 7 10 4 42 51 1 583 45 GI 2 
1504 4 2 10 4 1 7 1 782 45 GI 1 
1549 4 7 10 4 1 7 4 2406 45 GI 1 (22.03) 
1057, 1537 2 4 1 2 7 1 5 48 48 GI 2 
1524 7 4 5 2 11 1 5 429 48 GI 1 
1500 2 4 1 4 19 62 5 475 48 GI 1 
1033, 1043 43 4 1 2 7 1 5 505 48 GI 2 (6.29) 
1523 3 1 5 17 11 11 6 49 49 GI 1 
1569 9 25 2 10 22 3 6 52 52 GI 1 
1534 2 21 5 3 23 1 5 290 206 GI 1 
1027, 1522, 1554, 1562 9 2 4 62 4 5 6 257 257 GI 4 
1513 9 17 5 62 4 5 6 2543 257 GI 1 
1074 7 1 2 2 4 3 6 82 353 GI 1 
1538 7 17 5 2 10 3 6 353 353 GI 1 
1512 9 112 5 2 11 3 6 936 353 GI 1 
1527 7 2 5 2 2 3 6 2132 353 GI 1 
1071 7 17 5 2 13 3 6 3510 353 GI 1 
1552, 1568 8 10 2 2 11 12 6 354 354 GI 2 
1502, 1536 10 27 43 19 6 18 7 270 403 GI 2 
1570 7 17 2 15 23 3 12 51 443 GI 1 
1518 7 17 16 15 23 3 12 2687 443 GI 1 
1298 1 6 60 24 12 28 1 508 508 GI 1 
1501 10 1 50 99 120 76 52 678 677 GI 1 
1503, 1561 10 81 50 87 120 76 52 794 677 GI 2 
1573 2 1 29 28 58 25 58 1332 1332 GI 1 
* + 1553, 1557, 1563, 1572 
** + 1514, 1521, 1529, 1541, 1547, 1555, 1556, 1558, 1559, 1560 
 
a Sequence type 
b Clonal complex 
c UN, currently unassigned to a lineage 
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3.4.2 Association between clonal complexes and clinical symptoms.  
The distribution of the 122 C. jejuni isolates and comparison of the gastroenteritis, GBS 
and RA isolates were investigated (figure 3.1). The isolates from gastroenteritis were 
represented in all CCs except ST-61. GBS isolates were found in ST-22, 42 and 354 
complex. Isolates from RA were found in the ST-21, 45, 42, 48 and 61 complexes. The 
isolates from gastroenteritis were most frequently represented with the ST-21 (34%) 
and ST-45 complexes (23%), GBS isolates with the ST-22 (63%) and ST-42 complexes 
and RA more evenly distributed with the complexes ST-21 (28%), ST-45 (28%), ST-22 
(11%) and ST-48 (11%).  
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Figure 3.1. Distribution of the CCs among the 122 isolates with different clinical outcomes in this 
study. GI are shown in grey, GBS in white and RA in black. The ST-21 complex are shown to be the 
most frequent clonal complex followed by the ST-45 and ST-22 complexes. The GBS isolates are 
represented in the ST-22, ST-42 and ST-354 complexes and found to be significantly overrepresented in 
the ST-22 complex.   
 
The clonal complex frequencies varied within the three clinical outcome groups. For 
most frequent CCs appearing in at least two different clinical diagnosis types, the 
significance of association with diagnosis was confirmed by Fishers exact test. Both the 
observed frequency and the frequency expected under the hypothesis of no association 
(homogeneity) are given (Table 3.1). The cell frequencies show far more observed ST-
22 and ST-42 complexes than expected among GBS patients. Fishers exact test 
demonstrates a significant association between the CC and the diagnosis (p=0.0022).  
             
3.4.3 Phylogeny and clustering of the isolates 
The UPGMA dendrogram cluster analysis (figure 3.2) showed a grouping of isolates in 
relation to clonal complexes (shown with brackets). The sequelae (GBS and RA), 
marked in bold, were not found to clearly cluster within these groups. There is, 
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however, some evidence of clustering of GBS strains within the ST-22 complex even 
though there is a limited number of isolates. On the clonal frame genealogy (figure 3.3), 
the three different symptoms are found to be distributed evenly in the tree, not 
indicating any clustering of CCs or STs according to symptoms.  
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1033 48 505 GI 
1043 48 505 GI 
1057 48 48 GI 
1537 48 48 GI 
 
1524 48 429 GI 
1094 48 2955 RA 
1093 48 2955 RA 
 
1500 48 475 GI 
1520 21 1820 GI 
1032 21 50 GI 
1571 21 50 GI 
1567 21 50 GI 
1525 21 50 GI 
 
1506 21 1461 GI 
 
1551 21 24 GI 
1535 21 24 GI 
1515 21 3709 GI 
1548 21 53 GI 
1545 21 53 GI 
1544 21 53 GI 
 
1543 21 53 GI 
1526 21 53 GI 
1142 21 53 RA 
 
1172 21 53 RA 
1149 21 53 RA 
 
1566 21 21 GI 
1417 21 21 GI 
1418 21 21 GI 
1336 21 21 RA 
1565 21 2057 GI 
 
1516 21 1823 GI 
 
1572 21 388 GI 
1025 21 388 GI 
1563 21 388 GI 
1076 21 388 GI 
1557 21 388 GI 
1553 21 388 GI 
1422 21 388 GI 
1416 21 388 GI 
1517 21 815 GI 
 
1152 21 21 RA 
 
1058 21 251 GI 
1530 21 251 GI 
1550 21 251 GI 
1542 21 44 GI 
1540 21 44 GI 
1534 206 290 GI 
1573 1332 1332 GI 
 
1372 UN 3614 RA 
1209 UN UN RA 
 
1568 354 354 GI 
1552 354 354 GI 
1578 384 2049 GBS 
1523 49 49 GI 
1071 353 3510 GI 
1538 353 353 GI 
 
1527 353 2132 GI 
1512 353 936 GI 
1074 353 82 GI 
1319 UN 3708 RA 
1569 52 52 GI 
1518 443 2687 GI 
1570 443 51 GI 
 
 
1562 257 257 GI 
1554 257 257 GI 
1027 257 257 GI 
1522 257 257 GI 
1513 257 2543 GI 
1298 508 508 GI 
1312 61 219 RA 
 
1539 42 42 GI 
1533 42 42 GI 
1023 42 42 GI 
1582 42 1672 GBS 
1579 42 1672 GBS 
 
1049 22 22 GI 
1528 22 22 GI 
 
1313 22 22 RA 
1015 22 22 RA 
1581 22 22 GBS 
 
1580 22 22 GBS 
1576 22 22 GBS 
1575 22 22 GBS 
1084 22 22 GI 
1574 22 22 GI 
1047 22 22 GI 
1564 22 22 GI 
1577 22 267 GBS 
 
 
1519 22 2615 GI 
1231 45 45 RA 
1092 45 45 RA 
1560 45 45 GI 
1559 45 45 GI 
1558 45 45 GI 
1556 45 45 GI 
 
1555 45 45  
1006 45 45 GI 
1547 45 45 GI 
1541 45 45 GI 
 
1529 45 45 GI 
1091 45 45 GI 
1521 45 45 GI 
 
1514 45 45 GI 
1510 45 45 GI 
1508 45 45 GI 
1507 45 45 GI 
1504 45 782 GI 
1549 45 2406 GI 
 
1505 45 137 GI 
1037 45 137 RA 
 
1028 45 137 GI 
1532 45 137 GI 
1531 45 137 GI 
 
1511 45 583 GI 
1509 45 583 GI 
1014 45 2589 RA 
1046 45 2589 RA 
1561 677 794 GI 
1503 677 794 GI 
 
1501 677 678 GI 
1536 403 270 GI 
1502 403 270 GI 
 
 
Figure 3.2. Dendrogram demonstrating the phylogenetic relationship between the 122 isolates. 
Majority of strains were from patients with GI, strains from patients with sequelae (RA and GBS) are 
marked in bold. The isolates clustered in relation to clonal complexes (marked with brackets). A minor 
clustering of GBS to ST-22 was observed. 
Isolate CC ST Diagnosis 
48 
21 
353 
257 
22 
45 
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Figure 3.3. Clonal frame tree demonstrating the genetic relationships of STs between C. jejuni 
isolated from patients with GI, RA and GBS.  GI are shown as light grey, GBS white and RA dark 
grey. Combinations of sequelae are shown as GI + RA + GBS with squares and GI + RA with lines. The 
clonal frame tree includes GBS isolates from the MLST database (PubMLST).   
 
3.5 Discussion 
We have examined the association between C. jejuni genotypes and different clinical 
sequelae. C. jejuni isolates from a range of sources, geographical locations in Denmark 
and patients diagnosed with either gastroenteritis or RA were discriminated and formed 
the basis of our study. GBS isolates were added to the dataset from previously described 
cases outside the studied population. By using MLST the Danish isolates proved to be 
highly diverse with a total of 51 sequence types belonging to 18 clonal complexes. This 
finding is consistent with other studies examining C. jejuni isolates from a single 
geographic location (Duim et al., 2003; Mickan et al., 2007). However, our MLST data 
also identified a number of frequently described sequence types that have formerly been 
associated with human infection (Manning et al., 2003; Dingle et al., 2005; Sheppard et 
al., 2009b).  
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The ST-21 complex was particularly common with 38 %, similar to previous studies, 
where it accounted for up to 20 to 33 % of the isolates (Dingle et al., 2001a; Schouls et 
al., 2003; Sopwith et al., 2006, Karenlampi et al., 2007). The prevalence of the ST-21 
complex in Danish isolates is also found to be consistent with the MLST surveys of 
Campylobacter in other European countries, (Duim et al., 2003; Mickan et al., 2007; 
Kwan et al., 2008; McTavish et al., 2008). The other major clonal complex in our study, 
the ST-45 complex, accounted for approximately one quarter of the isolates and the ST-
48 complex was found with the frequency of 6.6%. These complexes have also been 
identified in other countries and from multiple sources (Dingle et al., 2001a; McTavish 
et al., 2008). Isolates from patients diagnosed with RA were not found to be associated 
with one or few of the clonal complexes. Therefore, we suggest that specific RA 
features rather involve differential expression of virulence factors that might be 
revealed by expression analysis of RA isolates or because of rapid recombination of 
disease associated genes. Furthermore, host specific genetics might be involved. 
 
The ST-22 complex accounted for 10% of the isolates and interestingly it was 
significantly overrepresented in the collection of GBS isolates both in our study as well 
as in the PubMLST database. The ST-22 complex was also described in isolates from 
several countries and animal sources (Duim et al., 2003; Kwan et al., 2008) but not as 
frequently as the ST-21 and ST-45 complexes. A study by Dingle et al. 2001b suggested 
a possible relatedness between the ST-22 complex and GBS isolates and this notion is 
supported by our data. Furthermore, the authors found that the ST-45 complex was 
underrepresented among GBS isolates (Dingle et al., 2001b). Once more our data and 
the GBS collection in the MLST database confirm this by the fact that to date no GBS 
isolates carry the ST-45, despite the fact that this is the most common sequence type 
identified in our study. The association between GBS and the two clonal complexes ST-
22 and ST-42 could be explained by a more frequently expression of the GBS-related 
Gm1 gangliosides, but we have no evidence of this. By comparison of the Danish 
isolates with the PubMLST database (including the global isolates), we found that the 
Danish isolates are similar to those obtained from other parts of the world and therefore, 
geographical location of the isolates is not correlated with sequence type. In addition, 
the global GBS isolates have been compared with the GBS isolates in our study and 
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shows the same results. In an earlier study, the GBS isolates were analysed by other 
methods and the population was found to be heterogenic (Engberg et al. 2001). Further 
analysis of the GBS isolates by DNA microarrays confirmed significant genomic 
heterogeneity among the isolates (Leonard et al., 2004). Despite these results, we 
believe that the results presented here together with those of others (Dingle et al., 
2001b) suggest a possible correlation between certain complexes, such as ST-22 
complex, and the development of GBS.       
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4. Identification of immunogenic and virulence associated 
Campylobacter jejuni proteins 
 
4.1 Abstract 
With the aim of identifying proteins important for host interaction and virulence, we 
have screened an expression library of NCTC 11168 C. jejuni genes for highly 
immunogenic proteins. A commercial C. jejuni ORF library consisting of more than 
1600 genes was transformed into the E. coli expression strain BL21 (DE3) resulting in 
2304 clones. This library was subsequently screened for immunogenic proteins using 
antibodies raised in rabbit against a clinical isolate of C. jejuni; this resulted in 52 highly 
reactive clones, which represented 25 different genes after sequencing. Selected 
candidate genes were inactivated in C. jejuni NCTC 11168 and the virulence was 
examined using INT 407 epithelial cell line. These investigations revealed Cj0034 to be 
a novel virulence factor and support the usefulness of the method.  
 
4.2 Introduction 
The food-borne pathogen, Campylobacter jejuni is a gram-negative, microaerophilic, 
spiral-shaped and motile bacterium. It is the most common cause of food- and water-
born gastroenteritis worldwide causing approximately 500 million human infections 
every year (Friedman et al., 2000; Skirrow et al., 2000). Infection is often associated 
with consumption of undercooked poultry meat, but water and other food sources also 
play a great role in the transmission of C. jejuni (Friedman et al., 2000). The symptoms 
of campylobacteriosis range from mild non-inflammatory, watery, self-limiting 
diarrhoea to severe abdominal cramps and bloody diarrhoea with fever and vomiting. 
Also post-infectious complications as reactive arthritis and Guillain-Barré syndrome are 
found to be associated with C. jejuni.  
 
Bacterial surface structures can interact with host tissue and could be responsible for the 
ability of C. jejuni to colonize the gastrointestinal tract of humans, which is believed to 
be essential for infection. A study has shown that C. jejuni isolated from patients with 
fever and diarrhoea revealed greater binding to epithelial cells compared to isolates 
from patients without fever and diarrhoea (Fauchere et al., 1986). Several mechanisms 
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involved in the survival and persistence of the bacteria in the gut are known, but far 
from enough to understand the complexity of virulence. Colonization of the gut is 
promoted by flagellar-mediated motility (Carrillo et al., 2004) and binding to host tissue 
like e.g. to fibronectin mediated by CadF and 1279c (Konkel et al., 1997). Furthermore, 
several other outer membrane proteins are found to be implicated in colonisation 
including MOMP (Moser et al., 1997), PEP1 (Leon-Kempis et al., 2006), Omp50 (Bolla 
et al., 2000), lipoproteins Omp18 (Burnens et al., 1995, Konkel et al., 1996), JlpA (Jin 
et al., 2001) and Cia proteins (Rivera-Amill et al., 2001). In addition, some of these 
surface exposed proteins are found to be immunogenic (Pei et al., 1998, Burnens et al., 
1995), which opens the possibility of vaccine development. Humoral immune response 
to a number of C. jejuni antigens is developed in most people upon an infection and 
epidemiological studies indicate that the immunity is crucial for the development of 
protection against Campylobacter disease (Tribble et al., 2010).  
 
The purpose of this study was to identify novel C. jejuni antigens and potential new 
virulence factors by screening a C. jejuni ORF expression library (Parrish et al. 2004) 
with serum from immunised rabbits. Selected candidates of the identified genes were 
examined for their role in virulence and tested as potential vaccine candidates. 
 
4.3 Material and methods 
4.3.1 Bacterial strains and plasmid 
The bacterial strains used in this study included E. coli SURE (Stratagene) and E. coli 
BL21 (DE3) (Stratagene) and the plasmid was pTLJ03. Strains and plasmid originates 
from a NCTC 11168 C. jejuni ORF library (Parrish et al., 2004) available from 
Geneservice. The expression clone set comprises of >1,600 C. jejuni ORF's and the 
expression vector pTLJ03 generates N-terminal GST-His-tagged fusion proteins. 
Strains were grown in LB media or the expression media MagicMedia (Invitrogen) at 
37 ºC. pTLJ03 containing strains were grown in media containing 50 µg/mL ampicillin 
unless otherwise specified. C. jejuni strains (NCTC 11168 and NCTC 11168H) were 
grown at 37 ºC microaerophilic on blood plates (BaseII and 5 % blood) in BHI broth or 
biphasic (blood plates and BHI broth) with antibiotic when needed (30 µg/mL 
kanamycin or/and 50 µg/mL streptomycin). 
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4.3.2 Expression library 
The library was originally created in E. coli SURE for optimal storage. The strain does 
not contain the T7 polymerase and for that reason the library was transformed to the E. 
coli BL21(DE3) expression strain. The clones were grown separately in microtiter 
plates in 200 µl LB media containing ampicillin overnight and subsequently the 
plasmids were purified as a pool and transformed to the chemocompetent E. coli BL21 
(DE3) strain. This revealed an expression library consisting of 2304 clones (24 
microtiter plates).     
 
4.3.3 Immunoblot assay 
Individual clones were grown 16-20 hrs in microtiter plates in MagicMedia for optimal 
expression. 2 µl of the culture was spotted on nitrocellulose membranes. The 
membranes were blocked in blocking buffer 30 min., washed in PBS tween and then 
incubated in primary antibody (1:1000) at 4°C for 16-20 hrs. The membranes were then 
washed in PBS tween and incubated in secondary antibody (Polyclonal goat anti rabbit 
immunoglobulins/HRP, Dako) for 1 hr. The reaction was visualised by 
chemoluminescence (chemoluminescent substrate, Invitrogen). The primary antibody 
was raised in rabbit immunised with a boiled-treated (100°C for 1 h) C. jejuni Penner 
serotype 2 originally isolated from a human patient. The Penner serotype 2 serum was 
chosen to correspond the serotype used in the commercial library (NCTC 11168). The 
serum was preincubated with E. coli BL21(DE3) before use to minimise background 
reaction. To verify that the antigens also reacted against human serum, a dot blot with 
10 selected clones expressing antigens and serum isolated from a patient infected with 
C. jejuni Penner serotype 2 was carried out as described above.   
 
4.3.4 Clone sequencing 
Plasmid DNA was isolated from 100 ml E. coli BL21(DE3) cultures using MidiPrep 
(Qiagen). Sequencing was conducted by Macrogen Inc. and the primer 5´GCT ATC 
CCA CAA ATT GAT AA 3´.     
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4.3.5 Recombinant DNA techniques 
Knock out mutants were kindly provided by Brendan Wren from the London School of 
Hygiene and Tropical Medicine, University of London. Their constructs were made via 
insertion of the Km cassette into unique sites present in pUC18-based recombinant 
plasmids containing random 1-2 kb fragments of the C. jejuni NCTC 11168 genome.  
 
Subsequently the gene knock outs were transferred from the 11168H strain used in 
Brendan Wrens laboratory to the 11168 strain used in our lab. Natural transformation 
was performed as described previously (Wang and Taylor, 1990) with some 
modifications. C. jejuni cultures grown overnight on BHI agar plates were collected and 
resuspended in 12 ml BHI broth to OD600 of 0.001. Bacterial suspensions in three 
dilutions were transferred to sterilized Petri dishes, incubated at 37°C with no shaking 
under micro aerobic conditions over night. 200 µg cultures with OD600 0.2-0.3 were 
transferred to sterilized tube with 1 ml BHI and incubated at 37°C with shaking under 
micro aerobic conditions 2 h. Then 10 ng of genomic DNA, purified with Qiagen blood 
and tissue kit) of the mutants, was added each tube. After additional incubation for 3 h, 
bacterial cultures were serially diluted and plated on BaseII agar plates with antibiotics 
(50 mg/l kanamycin). The agar plates were incubated at 37°C under microaerobic 
conditions 3 days. The mutants were checked for curved shape and motility before 
tested in assays.     
 
4.3.6 INT407 adhesion assay 
INT407 cells (representing intestinal cell line) were grown in MEM (+glutamax) media 
(Invitrogen) added 25 µg/ml gentamycin and 10% heat inactivated fetal bovine serum in 
5 % CO2. Cells were seeded at 2.5 x 10
5 pr well in 24 well plates, incubated overnight 
and checked for 100 % confluent monolayer. The E. coli clones were grown overnight 
in MagicMedia broth at 37°C and C. jejuni on blood agar plates microaerophilic at 
37°C. Immediately before assay, the OD600 of the bacteria was adjusted to 1 in PBS and 
1 ml bacteria culture was added the INT407 cells and cells were incubated with bacteria 
for 2 hours at 37°C, then resuspended and diluted in PBS and spotted on agar plates 
with appropriate antibiotics.  
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4.3.7 Electron microscopy 
To investigate, whether the C. jejuni mutant strain differed morphologically from the 
wild type strain, a transmission electron microscopy analysis was conducted. Initially, 
the bacterial cultures were fixated in 1% glutaraldehyde (EMS, Hatfield, USA) for 30 
minutes. To improve the adhesion of the bacteria, formvar coated 400-mesh copper 
grids were treated for 5 minutes with alcian blue (Sigma-Aldrich). The alcian blue 
treated grids were placed on top of cultures of C. jejuni NCTC11168 and C. jejuni 
NCTC11168∆0034, respectively, and after 5 minutes of incubation, most of the 
suspensions were removed from the grids with filter paper and the grids were stained 
for 30 seconds with phosphotungstic acid (BDH Chemicals). The grids were allowed to 
air-dry, and then they were viewed in a Morgagni 268D transmission electron 
microscope, and pictures were taken using a Mega-view III digital camera.   
 
4.3.8 Motility assay  
Motility assay was carried out to ensure no altered motility for the 11168∆0034 mutant. 
0.25 % soft agar plates were added 1 µl bacterial culture (OD600 adjusted to 0.1) in the 
middle of the plate and diameter was measured over a time period. 
 
4.3.9 Serum resistance assay 
Serum sensitivity assays were performed by modification of the method of Blaser et 
al.,1985. C. jejuni strains were grown overnight in Brucella biphasic cultures at 37°C, 
washed in PBS, pH 7.4, and adjusted to a concentration of 103 CFU/ml. C. jejuni cells 
(10-µl aliquots) were incubated in 240-µl pools of whole human blood (venous blood), 
human serum (whole blood incubated at 25°C 30 min, centrifuged 1000xg 10 min at 
4°C and supernatant isolated) and heat inactivated human serum (56°C for 30 min) 
respectively for 30, 60, 90 and 120 min. Following the incubation period, CFU was 
enumerated on BHI agar. 
 
4.3.10 Biofilm and autoagglutination 
Cell-to-cell autoagglutination was assayed in PBS as described by Misawa and Blaser, 
2000. Biofilm assay was made in 50 ml centrifuge tubes containing 25 ml inoculated 
Brucella broth with NTCT 11168 and the 11168∆0034 respectively. A glass slide was 
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added each tube and incubated micro aerobic for 48 h. Then the slides were stained with 
crystal violet and biofilm formation visualised.    
 
4.3.11 Protein purification  
His-tag purification was made with the already GST-His-tagged constructed vector 
from Geneservice. An overnight pre-culture of E. coli BL21(DE3) containing the 
vectors was 50-fold diluted to inoculate 1000 ml LB medium containing appropriate 
antibiotics. The cultures were incubated with shaking at 37 °C to an OD600 of 0.5, then 
induced with 10 mM IPTG and incubated with shaking for 16 hours at 30 °C. After 
induction, cells were lysed on ice in 20 ml lysis buffer (50 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidadole, 10 % glycerol) by addition of 1 mg/ml lysozyme followed by 
sonication. Lysates were cleared by centrifugation at 15,000xg for 30 min. Proteins 
were purified by nickel affinity chromatography using the Ni-NTA resin (Qiagen) 
equilibrated with lysis buffer and eluted with 250 mM imidazole. Eluted proteins were 
concentrated and dialyzed against 25 mM HEPES pH 7.5, 50 mM NaCl, 10 % glycerol.  
 
4.3.12 Mouse immunization 
To study the proteins ability of protection against infection, immunization of mice were 
carried out. Due to patent issues, the original nomenclature is not used for the genes in 
this study. Five proteins were tested for their ability to protect against C. jeuni infection; 
SSI-1, SSI-2, SSI-3, SSI-4, SSI-5 and Cj1228 (HtrA) was also included because of its 
known immunity and therefore a potential vaccine candidate. Mice (10 in each group) 
were immunized with 5 microgram/dose, except one with 1.6 microgram/dose (SSI-4), 
along with adjuvant (GNE, Intervet, NL). Four weeks after, the mice (Balb/c for 
colonization and CH3/HeN for invasion) were treated for three days with streptomycin 
(5 g/l in drinking water) and challenged one day later with C. jejuni 81-116 (6x105 
CFU, colonization study) and 72Dz/92 (5x107 CFU, invasion study) respectively. 
Balb/c mice 6-8 weeks (female) were used in groups of three. One fresh faecal dropping 
was collected and weighted from each animal and dilutions were made in order to 
determine CFU/gram faeces. Faecal samples were collected from the Balb/c mice 
regularly in 23 days. Necropsy was prepared one week after challenge of the CH3 mice, 
spleen and liver were collected and CFU/organ measured.  
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4.3.13 Predictions of protein localization  
Prediction of protein localization and amount of transmembrane helixes was made by 
TMHMM 2.0 server (Moller et al., 2001). The SignalP 3.0 server predicts the presence 
and location of signal peptide cleavage sites in amino acid sequences. The method 
incorporates a prediction of cleavage sites and a signal peptide/non-signal peptide 
prediction based on a combination of several artificial neural networks and hidden 
Markov models (Emanuelsson et al., 2007). The LipoP 1.0 server produces predictions 
of lipoproteins and discriminates between lipoprotein signal peptides, other signal 
peptides and N-terminal membrane helices in Gram-negative bacteria (Junker et al., 
2003). All three servers are available at http://www.cbs.dtu.dk/services/. 
 
4.4 Results 
4.4.1 Identification of C. jejuni antigens. 
With the aim of identifying immuno-reactive C. jejuni proteins plasmid DNA was 
isolated from a pooled mixture of commercial library clones established by Parrish et al 
(2004) in the plasmid pTLJ03 (Parrish et al., 2004). Plasmid DNA was transformed into 
E. coli BL21 to allow expression from the T7 promoter. The resulting transformants 
were individually spotted on a nitrocellulose membrane and reacted with serum isolated 
from a rabbit infected with a C. jejuni serotype 2. The immuno-screening revealed 
several immunogenic E. coli clones as shown in figure 4.1.  
Figure 4.1: Immunoblot assay screen. The figure show a representative immunoblot assay with 96 E. 
coli clones each expressing a C. jejuni gene reacting against rabbit serum. Dots with a strong reaction 
where isolated and the genes sequenced. A total of 52 clones were sequenced representing 25 genes. 
Lower left dot is the BL21 expression strain with no insert and the right a media control.   
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Inserts in vectors isolated from the most immunogenic clones were selected for 
sequencing and from a total of 2304 clones, 52 inserts were sequenced representing 25 
genes (table 4.1). 
 
Table 4.1. Sequenced highly immunogenic clones.  
Cj number Gene  Protein ID                            Class*     Predicted mass (kDa) 
Cj0014c   Putative integral membrane protein  3.C.1  20.3 
Cj0034c4   Putative periplasmic protein   3.C.5  26.4 
Cj01113   Putative periplasma protein  3.C.5  29.2 
Cj0203    Putative transmembrane transport protein 4.A.6  48.2 
Cj0383c  ribH 6,7-dimethyl-8-ribityllumazine synthase  1.G.9  16.6 
Cj04043   Putative transmembrane protein  3.C.1  30.7 
Cj0408  frdC Fumerate reductase cytochrome B subunit  1.B.3  30.0 
Cj0477  rplL 50S ribosomal protein   3.A.2  13.0 
Cj0525c3  pbpB Putative Penicillin binding protein   3.C.4  68.3 
Cj06452   Putative secreted tranglycosylase  3.C.4  42.8 
Cj0774c5  ABC transport system ATP binding protein 4.A.6  37.9 
Cj0811   lpxK Tetrasyldisaccharide 4’-kinase   3.C.2 36.2 
Cj0917c  cstA Carbon starvation protein A homolog  3.C.1  75.7 
Cj0965c   Putative acyl-CoA thiosester hydrolase 6.A 14.4 
Cj1092c  secF Protein-export membrane protein  4.E  36.1 
Cj1094c  yajC Preprotein translocase subunit   4.E  10.1 
Cj1163c4   Putative cation transport protein  4.A.2 35.8 
Cj11743   Putative efflux protein   5.D 11.2 
Cj1292   Dcd Deoxycytidine triphosphate deaminase  1.F.3 20.6 
Cj1364c  fumC Fumerate hydratase    1.B.3  50.7  
Cj13712   Putative periplasmic protein (vacJ homolog) 4.1 26.5 
Cj1382c4  fldA Flavodoxin    1.B.7 17.1 
Cj1529c5  purM Phosphoribosylaminoimidazole synthase 1.F.1 35.6 
Cj1628  exbB2 Putative exbB/tolQ family Transport protein  4.A.6  15.7 
Cj1632c   Putative periplasmic protein  3.C.5  6.0 
* Class due to Welcome Trust Sanger Intitute (http://www.sanger.ac.uk/Projects/C_jejuni/). Numbers in 
superscript are the amount they were identified as strong reactors against the rabbit antiserum and 
sequenced. 
 
Classes: 
1.B.3 Tricarboxylic acid cycle 
1.B.7 Electron transport 
1.F.1 Purine ribonucleotide biosynthesis 
1.F.3 2’-deoxyribonucleotide biosynthesis 
1.G.9 Riboflavin 
3.A.2 Ribosomal protein syntesis and modification 
3.C.1 Membrane, lipoprotein and porins 
3.C.2 Surface polysaccarides, lipopolysaccharides and antigens 
3.C.4 Murein sacculus and peptidoglycan 
3.C.5 Miscellaeneous periplasmic prot. 
4.A.6 Other cell process 
4.E Protein and peptide secretions 
4.I Pathogenicity 
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Ten of the 25 clones (Cj0034, Cj0203, Cj0404, Cj0525c, Cj0645, Cj0917c, Cj1094c, 
Cj1371, Cj1382c, Cj1632c) were further tested for reaction against human antiserum 
Penner serotype 2 and were found positive (figure 4.2). The ten clones were selected 
either because of a repeatedly strong reaction against the rabbit antiserum (Cj0034c, 
Cj0404, Cj0525c, Cj0645, Cj1382c), its predicted membrane associated localization 
(Cj1094c), already existing knowledge from other pathogens (Cj0917c, Cj1371), 
predicted to be only in Campylobacter (Cj1632c) or because of an also altered 
autoagglutination phenotype (Cj0203). 
 
 
Figure 4.2. Immunoblot assay with human serum. The clones Cj0034, Cj0203, Cj0404, Cj0525c, 
Cj0645, Cj0917c, Cj1094c, Cj1371, Cj1382c, Cj1632c, from left to right, were tested for its reactivity 
against the antiserum isolated from a human patient infected with a C. jejuni serotype 2. All the clones 
reacted more or less with the serum. Lower left is a medium control and lower right a BL21(DE3) control 
(not easy to see).  
 
The genes sequenced from the immunogenic E. coli clones, were analysed with the 
definitions of functional classification given at the Welcome trust Sanger Institute 
webpage (http://www.sanger.ac.uk/Projects/C_jejuni/). The 25 genes were distributed 
over five of the six classification groups. Nine of the 25 genes in group 3 
“Macromolecule metabolism” all in subgroup 3.C “Cell envelope”, which further 
contain the groups; 3.C.1 Membranes, lipoproteins and porins, 3.C.2 Surface 
polysaccharides, lipopolysaccharides and antigens, 3.C.3 Surface structures, 3.C.4 
Murein sacculus and peptidoglycan and 3.C.5. Miscellaneous periplasmic proteins. The 
Nine genes were mainly found in the subgroups 3.C.1 and 3.C.5. The remaining 16 
genes were located in the groups of small molecules metabolism, cell processes 
(including transport/binding proteins and pathogenicity), and other (drug sensitivity).  
 
4.4.2 Prediction of protein localization 
Prediction of localization of the proteins and amount of transmembrane helixes was 
made by TMHMM 2.0 server (Moller et al., 2001), prediction of signal peptide 
molecule with SignalP 3.0 server based on hidden Markov models (Emanuelsson et al., 
2007) and prediction of lipoproteins with LipoP (Junker et al., 2003).  
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Results are shown in table 4.2. 
 
Table 4.2. Localization of the proteins and possible signal peptide molecule predicted by TMHMM, 
SignalP and LipoP 
    Transmembrane               Predicted signal peptide 
Cj number     Localization         Helixes                     (probability)         Lipoprotein  
Cj0014c  Inside and outside        3    yes (0.951)              TMH 
Cj0034c  Inside and outside        1                               yes (0.999)                SpI  
Cj0111   Inside and outside        1   no                          CYT 
Cj0203   Inside and outside        12   no                                  TMH  
Cj0383c  Outside                     0   no                                   CYT 
Cj0404   Inside and outside        1               no                CYT 
Cj0408  Inside and outside        5   no                                   TMH 
Cj0477  Outside                       0                    no                CYT 
Cj0525c  Inside and outside        1                            no                                    TMH 
Cj0645   Outside                    0   yes (0.992)                      SpI 
Cj0774c  Outside                       0   no                CYT 
Cj0811   Inside and outside        1      no                                      TMH 
Cj0917c  Inside and outside       16                                 yes (0.940)                TMH 
Cj0965c  Inside                       0                            no                CYT   
Cj1092c  Inside and outside        4                                  no                 TMH   
Cj1094c  Inside and outside        1                                  no                  CYT  
Cj1163c  Inside and outside        6                              no                 CYT 
Cj1174   Inside and outside        4                                  no                                     TMH  
Cj1292   Outside                         0      no                 CYT   
Cj1364c  Outside                      0    no                 CYT  
Cj1371   Outside              0    yes (1.000)                SpI  
Cj1382c  Outside                         0                                  no                 CYT 
Cj1529c  Outside                         0                                  no                                      CYT 
Cj1628  Outside and inside        3     no                  TMH 
Cj1632c  Outside                      0                                  yes (0.999)                SpI     
TMH: Transmembrane helixes, SpI: Signal peptidase I, SpII: Lipoprotein signal pepdidase II, CYT: 
cytoplasmic or all the rest.  
 
14 out of 25 proteins are predicted to contain one or more membrane helixes, two of 
them further with a signal peptide. The location of ten proteins is predicted to be 
outside, where three of them harbor a signal peptide. None of the proteins were 
predicted to contain a lipoprotein signal peptidase. 
 
4.4.3 Virulence detection by use of cell adhesion assay 
For 10 selected E. coli clones INT407 cell line adhesion assay was performed in 
triplicates (figure 3.3). The assay showed an enhanced adhesion ability of several of the 
clones (Cj0034c, Cj0404, Cj1371).  
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Figure 4.3. INT407 cell line assay. CFU/ml for E. coli clones expressing the respective genes.  
 
Subsequently, gene-specific C. jejuni mutants, were tested in the same cell adhesion 
assay. For that purpose mutations were first successfully transferred from NCTC 
11168H to NCTC 11168 by natural transformation and checked for curved shape and 
motility. The cell adhesion assay showed a reduced ability to adhere to INT407 cells for 
the mutant, Cj0034c (figure 4.4).  
1,E+00
1,E+01
1,E+02
1,E+03
1,E+04
1,E+05
1,E+06
11168 Cj0034 Cj0645 Cj0917 Cj1371
lo
g
C
F
U
/m
l
 
Figure 4.4. INT407 cell line assay. CFU/ml of knock out mutants of C. jejuni 11168 ∆Cj0917, 
∆Cj0034c, ∆Cj1371, and ∆Cj0645 compared to the NCTC 11168 wildtype. Standard barrs indicate 
standard deviations. 
 
We further confirmed, by means of electron microscopy, that the mutation in Cj0034 
did not result in major structural changes of the bacterial cell morphology (figure 4.5).  
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Figure 4.5. Electron microscopy of C. jejuni NCTC 11168 left and C. jejuni NCTC11168∆0034 right   
 
In addition, serum resistance, motility, auto agglutination and biofilm formation, were 
determined but no differences were observed compared to wild type for the C. jejuni 
mutant.    
 
4.4.4 Mouse immunization 
Several proteins were selected to test as vaccine components in two Campylobacter oral 
challenge mouse models; one in C3H/HeN mice in which invasion in liver and spleen 
was measured and the other in Balb/c mice in which shedding faeces was determined. 
The challenge study (figure 4.6) showed a reduced invasion into spleen and liver for at 
least two of the proteins; SSI-2 and SSI-3. Challenge colonization results are shown in 
figure 4.7, where no decreased colonization for any of the proteins was observed.  
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Figure 4.6. Challenge invasion study. Invasion of C. jejuni 72Dz/92 in spleen and liver of C3H/He 
mice, 6 days after challenge. Values determined individually, log-transformed (log 1+CFU) and 
calculated as averages per group. Error bars indicate standard deviation. The mice were immunized with 
SSI-1 to SSI-6 before challenge. 
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Figure 4.7. Challenge colonization study. Colonization of Balb/c with C. jejuni strain 81116 after 
challenge. Individual colonization was determined per 0.2 feacal pellet, lot-transformed and calculated as 
average per group. The mice were immunized with SSI-1 to SSI-6 before challenge. 
 
 
4.5 Discussion 
In this study we have successfully identified immuno-reactive proteins of the important 
human pathogen, C. jejuni. An E. coli library expressing single C. jejuni proteins was 
screened using specific antibodies from rabbit resulting in the selection of immuno-
reactive proteins among the total amount of antigens in C. jejuni.  
 
Identification of surface structures is important to understand the virulence of C. jejuni  
particular in relation to interaction with the host. Mechanisms like colonization, 
adhesion and invasion, biofilm formation and immune evasion are essential for the 
pathogen to establish a successful infection. We identified proteins predicted to be 
surface related by the classification of Sanger Institute and bioinformatical predictions. 
14 proteins were predicted to contain one or more membrane helixes, three of them with 
predicted signal peptide. Another three proteins were predicted to maintain a signal 
peptide and only one protein was predicted to solely be located inside the cell. Based on 
predictions, the majority of the proteins are exposed to the surface and these findings 
back up the validity of our approach aimed at isolation of novel surface proteins.  
 
Several other studies have been published with the aim to identify these structures. The 
work by Cordwell et al (2008) identified proteins using 2-DE/MS and 2-DLC/MS/MS 
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found several proteins also identified in this study (Cj0034c, Cj0404, Cj0917c, 
Cj0774c, Cj1092, and Cj1094). A study by Prokhorova et al (2006) used proteomics for 
the detection of various Campylobacter surface proteins and demonstrated that some of 
them further were protective in a C. jejuni colonization model. They did, as in this 
study, identify flavodoxin (Cj1382c) with high significance of identification but the 
protein was not studied in the mouse vaccination-challenge experiment. Flavodoxin was 
also identified in a proteomic analysis by Seal et al (2007), where proteins expressed in 
a robust chicken colonizer strain were compared with a poor chicken coloniser strain. 
Flavodoxin was along with Cj1292 (deoxycytidine triphosphate deaminase) identified 
in the high colonizer strain.  A study by Garenaux, et al (2008) found the flavodoxin 
protein to be over-expressed after exposure to paraquat, suggesting the protein could 
play a role in C. jejuni oxidative stress resistance.  Kaakoush et al (2007) identified 
eighteen genes bioinformatically as potential contributors to the differences in oxygen 
tolerance between strains. Cj0203 was, among others, considered the top potential 
contributor and the gene was over expressed along with important surface adhesins such 
as CadF and FlaA, indication a potential role of oxygen as trigger of transcription of 
these genes.  
 
In this study, we found several interesting and potential important genes and because of 
altered adhesion ability, we choose further investigations of the Cj0034c. It was found 
to be important for adhesion to INT407 epithelial cells by a reduction of adhesion of the 
Cj0034c mutant, which also correlated with the E. coli INT407 cell assay where 
Cj0034c showed some enhanced adhesion to the cells. Therefore, it could have a 
correlation to and importance for virulence. The gene is grouped in the 3.C.5 
Miscellaneous periplasmic proteins together with other very important antigenic and 
virulence genes, such as PEB2, 3 and 4. Cj0034c is a 26.4 kDa putative periplasmic 
protein found in other C. jejuni subspecies. It was predicted to contain one helix and 
one signal peptide, which most likely makes it surface exposed and therefore a target 
for the immune system. Furthermore does the outside exposure it likely that it 
contributes to host interaction by adhesion to epithelial cells. 
 
Vaccination challenge experiments showed that SSI-2, SSI-3 and SSI-5 resulted in the 
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best protection against invasion in spleen and liver. SSI-2 is a large antigen, not likely 
to be expressed by a vaccine strain. SSI-5 is a smaller antigen that might be suitable for 
expression in the vaccine strain but SSI-3 is also a small molecule and was easily 
produced by E. coli BL21(DE3) during purification. In addition, SSI-3 gave the best 
protection against invasion and some against colonization. Therefore we propose that 
SSI-3 is a good vaccine candidate against C. jejuni.  
 
4.6 Acknowledgements 
The authors thank Brendan Wren for providing the C. jejuni mutants, David Ussery and 
Carsten Friis for support with prediction of protein localization, Ruud Verstegen for 
technical assistance during immunization experiments, and Marian Jørgensen for 
critical manuscript proof reading. This project is funded by Statens Serum Institut, 
University of Copenhagen and FOBI Research School.   
 
 
 
 
 
 
 
 
 54 
Chapter 5. Screening for virulence associated phenotypes of 
Campylobacter jejuni. 
   
5.1 Abstract 
Campylobacter jejuni has been identified as the leading cause of food-borne bacterial 
gastroenteritis in the developed world, including Denmark. Compared to other 
important pathogens, less is understood concerning the virulence factors of this human 
pathogen. It is well established that the surface of C. jejuni is crucial for its ability to 
colonize, persists and cause disease in humans. Surface structures have been identified 
in C. jejuni to be important for adhesion to epithelial cells and/or biofilm formation and 
further found also to play a role in virulence development. The aim of this work was to 
identify novel proteins involved in cell-cell contact (autoagglutination), biofilm 
formation and adhesion to epithelial cells using an E. coli open reading frame library 
expressing genes from C. jejuni NCTC 11168. 
 
5.2 Introduction 
Campylobacter jejuni is the leading cause of food-borne bacteria diarrhoea in the 
developed world, including Denmark with 3352 cases in 2009. The major source of 
infection is consumption and handling of contaminated and undercooked poultry 
products. Infection with this organism can lead to acute illness as well as serious life-
threatening consequences, such as Guillain-Barré syndrome (Allos, 1997). Even though 
diarrhoeal infection with C. jejuni is more frequent than Salmonella, understanding of 
C. jejuni pathogenesis and the critical virulence factors is far from understood.  
 
Autoagglutination (AAG) has been known as an indicator for virulence in other gram-
negative pathogens, including Vibrio cholera, Bordetella pertussis, Neisseria 
gonorrhoeae and Yersinia (Chiang et al., 1995; Menozzi et al., 1994; Swanson et al., 
1971; Laird and Cavanaugh, 1980). To date, the role AAG in C. jejuni pathogenesis has 
not been determined but associations with adherence and invasion and a strong 
association to surface proteins and the flagella have been found (Misawa and Blaser, 
2000). In addition, studies have shown a relation between AAG and flagellin 
glycosylation (Golden and Acheson, 2002; Guerry et al., 2006). AAG has furthermore 
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been found to be dependent on quorum sensing (Jeon et al., 2003). Biofilm, or cell 
surface associated growth, is another form of cell community growth, which was found 
important for environmental stress resistance, such as desiccation and antimicrobials, as 
well as increased resistance to host defences in a number of bacterial pathogens 
including C. jejuni (Davis et al., 2002). In C. jejuni, the flagella has been found to be 
implicated in biofilm formation but the complete molecular understanding is not 
established. Adhesion to epithelial cells is crucial for C. jejuni and its interaction with 
the host and some adhesion factors have been studied, including MOMP (Moser et al., 
1997), PEP1 (Leon-Kempis et al., 2006), Omp50 (Bolla et al., 2000), lipoproteins 
Omp18 (Burnens et al., 1995, Konkel et al., 1996), JlpA (Jin et al., 2001) and Cia 
proteins (Rivera-Amill et al., 2001). C. jejuni has in previous studies been found 
positive for haemolytic activity depending on culture conditions (Arimi et al., 1990; 
Misawa et al., 1995). So far, two genes in C. jejuni have been associated with 
haemolytic activity: ceuE and pldA. The CeuE protein is a lipoprotein that functions as 
a periplasmic binding protein. It is a part of an ABC transport system associated with 
enterobactin transport across the inner membrane (Stintzi et al., 2008). pldA, encoding 
phospholipase A, has been studied for C. coli and found to contribute to cell-associated 
haemolysis (Grant et al., 1997). A homologue of pldA is also present in the genome of 
C. jejuni NCTC 11168 (Parkhill et al., 2000).  
 
In this study, the aim was to identify genes important for adhesion, persistence and 
virulence in C. jejuni by screening a commercial E. coli Open Reading Frame (ORF) 
library.  
 
5.3 Material and methods 
5.3.1 Strains, plasmids and growth conditions 
The bacterial strains used in this study included E. coli SURE (Stratagene) and E. coli 
BL21(DE3) (Stratagene) and the plasmid was pTLJ03 (Parrish et al., 2004). Strains and 
plasmid originates from a C. jejuni ORF library created by Parrish et al (2004) available 
from Geneservice. The expression clone set comprises of  >1,600 C. jejuni ORF's and 
the expression vector pTLJ03 generates N-terminal GST-His-tagged fusion proteins. 
Strains were grown in LB media or the expression media MagicMedia (Invitrogen) at 
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37ºC. Clones containing pTLJ03 containing strains were grown in media containing 50 
µg/ml ampicillin unless otherwise specified. The library was originally created in E. 
coli SURE for optimal storage. The stain does not contain the T7 polymerase and for 
that reason the library was transformed to the E. coli BL21(DE3) expression strain. The 
clones were grown separately in microtiter plates in 200 µg LB media containing 
ampicillin overnight and subsequently the plasmids were purified as a pool and 
transformed to the chemocompetent E. coli BL21(DE3) strain. This revealed an 
expression library consisting of 2304 clones (24 microtiter plates). The variability of the 
clones was verified by comparison of protein expression of randomly selected clones on 
a SDS-PAGE gel.  
 
5.3.2 Screening for autoagglutination 
Autoagglutination assay for E. coli clonal library was studied in microtiter plates. E. 
coli BL21(DE3) clones were grown and induced over night in 200 µl MagicMedia 
(Invitrogen) in microtiterplates and the next day the wells were inspected by 
visualisation for autoagglutination. Only the clones with clear and high amount of 
autoagglutination were considered positive. Negative controls of E. coli BL21(DE3) 
were included.  
 
5.3.3 Biofilm formation in microtiter plates  
Screening for biofilm formation was performed in microtiter plates in MagicMedia 
(Invitrogen) containing appropriate antibiotics. A replicator was used to inoculate 3 
sterile 96-well flat/bottom microtiter plates in succession. The inoculated plates were 
then grown at 37°C for 24 hours, after which the media was discarded. The wells were 
then washed twice with 200 µl Phosphate-Buffered Saline (PBS) and 150 µl 0.1% 
crystal violet was added to each well and discarded after 15 min. Then washed with 200 
µl PBS twice. The remaining crystal violet was dissolved in 150 µl 96% ethanol for 30 
min. An OD620 reading was made on ELISA reader and the average for each well was 
determined. Negative controls of E. coli BL21(DE3) were included.  
 
5.3.4 HeLa cell line adhesion assay  
Adhesion to epithelial cells was studied using a HeLa cell line kindly provided from the 
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Department of Virology, Statens Serum Institut as a monolayer. DME media 
(Invitrogen), supplemented with 10% heat inactivated fetal bovine serum and 
antibiotics, was disposed and the wells were washed three times with 0.5 ml PBS for 5 
min at 100 rpm. 0.5 ml fresh DME media without antibiotics was then added each well. 
E. coli BL21(DE3) ORF clones were grown and thereby induced overnight in 
MagicMedia (Invitrogen) and the next day diluted to 10-2. 12.5 µl bacterial culture was 
added to each well and the plates were left at 37 °C for 3 hours. After inoculation, each 
well was rinsed three times with PBS. Adherent bacteria were released by the addition 
of 200 µl 0.5% Triton X-100 (Sigma). PBS was then added and adherent bacteria were 
quantified by plating appropriate dilutions on LB agar medium. Control wells were 
prepared in a similar manner but without treatment as a number of total cells. Specific 
adhesion to HeLa cells was expressed by the percentage of number of CFU adhering to 
HeLa cells minus total number of CFU.  
 
5.3.5 Haemolysis  
The E. coli ORF library was screened for hemolytic activity. Defibrinated sheep blood 
was washed in PBS, centrifuged at 400×g in 5 min at 4°C. This process was performed 
3 times. Erythrocyte suspension were adjusted to 16% (8% of total volume when added 
to each well) with PBS supplemented with 0.1% BSA. 100 µl MagicMedia was added 
each well in microtiter plates. E. coli clones from the ORF library were transferred from 
master plate wells to three replica wells using replicator. Plates were incubated for 24 
hours at 37 ˚C under a gas mixture of 92% N2, 5% CO2 and 3% O2 under humid 
conditions. 100 µl of 16% washed sheep blood (0.1 % BSA) was then added to each 
well. After incubation, the plate was centrifuged at 2.200×g for 20 min, supernatant 
(100 µl) was taken from each well and transferred to another microtiter plate for OD550 
measurement in a microplate reader. Wells with the highest values were rerun with 6 
replicas using this procedure. 
 
5.3.6 Growth in chicken mucus 
Mucus was recovered from the intestines of eleven 30 days old chickens kindly 
provided by the hatchery DanHatch. The chickens were fasted for 1 day before the 
intestines were obtained. Three sections of the intestines were isolated; jejunum, ileum 
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and the two colic ceca (figure 5.1). The sections were placed in petri dishes containing 
PBS and kept on ice. The intestines were cut open and washed with buffer, and each 
section was transferred to a petri dish with fresh PBS buffer, where the mucus was 
scraped off the intestine walls.   
Figure 5.1. Isolation of chicken intestine mucus. Three sections of the chicken intestine were isolated; 
jejunum, ileum and ceca.  
 
All the scraped material from each type of section was centrifuged 15 minutes at 
10,000x g, and the supernatants were recovered. The mucus was checked for possible 
Campylobacter contamination by plating on blood plates and CCDA plates and 
incubated at 37°C and 42°C, for three days. The mucus was stored at -20°C. Prior to 
use, the mucus was sterilized by treatment with UV-light for 15 minutes and tested for 
contamination on LB agar plates, finally, the protein concentration was measured and 
adjusted to 1 mg/ml. 
 
Screening of clones with enhanced growth ability in chicken mucus was studied by 
inducing the clones individually in MagicMedia, and then inoculating mucus from the 
three isolated intestinal sections were with a pool of 96 clones. The pool of clones, 
inoculated in the three sections respectively, was grown over night and present clones 
isolated in a dilution row. Three clones, from each experiment, were isolated from the 
highest dilution of an overnight culture, the plasmid purified, as described in section 
4.3.6 and then ran on a 1% agarose gel. The screening was made for 288 clones (three 
times 96 clones). 
 
5.3.7 Plasmid purification and sequencing 
Plasmids from overnight cultures grown in LB media were purified using a QIAfilter™ 
Plasmid Midi Kit and plasmids were sequenced by Eurofins mwg operon, using their 
Value Read service. 
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5.3.8 Prediction of protein localization 
Prediction of protein localization and amount of transmembrane helixes was examined 
by TMHMM 2.0 server (Moller et al., 2001). The SignalP 3.0 server predicts the 
presence and location of signal peptide cleavage sites in amino acid sequences. The 
method incorporates a prediction of cleavage sites and a signal peptide/non-signal 
peptide prediction based on a combination of several artificial neural networks and 
hidden Markov models (Emanuelsson et al., 2007). The LipoP 1.0 server produces 
predictions of lipoproteins and discriminates between lipoprotein signal peptides, other 
signal peptides and n-terminal membrane helices in Gram-negative bacteria (Junker et 
al., 2003). All three servers are available at http://www.cbs.dtu.dk/services/. 
 
5.4 Results 
To identify genes important for C. jejunis virulence and/or interaction with the host, 
several assays with an E. coli ORF library were used, including autoagglutination assay, 
biofilm formation assay, HeLa cell adhesion assay and haemolysis assay. 
 
5.4.1 Screening for autoagglutination positive clones 
A commercial ORF library was screened for autoagglutination in microtiterplates 
(figure 5.2). A total of 2304 clones were screened and 41 wells were found positive for 
autoagglutination. The result was solely achieved by visualization.  
 
Figure 5.2. Screening for autoagglutination. The screening for autoagglutination was made in 
microtiter plates with overnight induced E. coli BL21(DE3) containing plasmid with various gene inserts. 
The well in the middle represent a strong autoagglutinating clone. 
 
Of the 41 identified clones, 7 genes were successfully sequenced and identified. The 
identified genes were: Cj0108, Cj0121, Cj0125, Cj0203, Cj0434, Cj1223 and Cj1717. 
 
5.4.2 Screening for biofilm formation 
In order to identify E. coli clones with altered phenotype according to biofilm 
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formation, a screening of the total library (2304 clones) in microtiter plates was made. 
The clones were induced overnight and the amount of biofilm was measured in 
microtiter plates by visualisation and OD measurement. Several clones where 
reproducible found to form biofilm (figure 5.3), and by sequencing four of these clones 
were found to encode the genes Cj0525c, Cj0774c, Cj0034 and Cj0404. 
 
 
 
 
  
Figure 5.3. Screening for biofilm formation. Screening for biofilm formation was made in 
microtiterplates. A: Biofilm formation in larger wells with selected clones producing relatively strong 
biofilm. B: Microtiter plates from the initial screening with 3 replica showing the reproducibility.     
 
5.4.3 HeLa cell adhesion assay 
Adhesion to epithelial cell is recognised as being important for the pathogenesis of C. 
jejuni in the human host. A HeLa cell adhesion assay was used in order to identify C. 
jejuni adhesion factors, which could promote cell adhesion in an E. coli background.  A 
total of 288 clones were screened for adhesion to HeLa cells. Clones showing improved 
adhesion were investigated in a secondary experiment where growth rate was taken into 
account. Figure 5.4 shows the results for the secondary experiment.   
 
 
 
 
 
 
 
 
 
 
 
  A 
B 
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Figure 5.4. HeLa cell adhesion assay. Adhesion to HeLa cells was initially tested for 288 clones. Of 
them 33 clones with enhanced adhesion were tested in a secondary experiment. Y-axis shows CFU/CFU 
and X-axis the different clones. 12 clones adhered twofold or more to the HeLa cells compared to the 
control (BL21(DE3) without insert).  
 
The HeLa cell line assay revealed 12 clones that adhered double or more the value of 
the control (BL21(DE3) without insert). Because of sequencing problems, only one 
clone was identified as Cj0408 by sequencing. The implausible value of 1.3 CFU 
adhering per CFU in the well must be ascribed to deviations in the assay.  
 
5.4.4 Haemolysis assay  
Haemolysis was measured with a microplate reader and results are shown at figure 5.5. 
It illustrates the OD550 values of the wells of a) microtiter plate (Mp) 1,2 and 3 b) OD550 
values from Mp 4 to12 and c) OD550 values from 13 to Mp 21. 
 
 
Figure 5.5. Haemolysis assay. Haemolysis was measured on a microplate reader as the amount of lysed 
defibrinated sheep blood when incubated with different E. coli BL21(DE3) expressing genes from C. 
jejuni. Y-axes are showing the OD550 values and the wells with the 2304 clones on the X-axis.  
 
Clones with a high reaction were repeated with 6 replicas with following result: 
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    Microtiter plate                    well                        OD550 value 
 Mp1        A2   0.120 
 Mp1                     A6   0.115 
 Mp2        A8   0.118 
 Mp3        H4   0.117 
 Mp10        F8   0.109 
 Mp10        F10   0.103 
 Mp12              D3   1.433 
 Mp12        C3   0.137 
 Control 
 E. coli BL21(DE3) with empty pTLJ03 0.102 
 
One clone (Mp12D3) showed a promising result and was subsequently inoculated on a 
plate with LB agar (100 µg/ml amp) and incubated at 37˚C for 24 hours. 4 colonies 
were isolated and all tested negative for haemolytic activity. Therefore a contamination 
was suspected and microscopy confirmed the fact. Because of the contamination and 
the in general low values and small differences between the E. coli BL21(DE3) with 
empty pTLJ03 and the E. coli clones in the experiment, we chose to stop further 
experiments. 
 
5.4.5 Selection of clones after growth in chicken mucus 
96 E. coli BL21(DE3) clones were pooled and grown in three sections of mucus 
isolated from cecum, jejunum, and ileum respectively. This was made to examine if 
some of the clones would be selected due to enhanced growth abilities in chicken 
mucus. Three clones were isolated from the highest dilution of an overnight culture. 
Figure 5.6 show the results obtained in the three sections of mucus. 
                  A         B                                            C    
            
Figure 5.6. Selection of E. coli BL21(DE3) clones in chicken mucus. Pool of 96 E. coli BL21(DE3) 
clones, were grown overnight in three different sections of chicken intestinal mucus. A: Mucus isolated 
from cecum with purified vectors from three clones (x, y and z) in three pools (MP1, 2, 3). B: Mucus 
isolated from ileum with purified vectors from three clones (x, y and z) in three pools (MP1, 2, 3). C: 
Mucus isolated from jejunum with purified vectors from three clones (x, y and z) in three pools (MP1, 2, 
3).   
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No obvious selection of the clones was observed, except in the mucus from jejunum 
with clones from pool two (MP2). It was not possible to sequence the gene for this 
clone 
 
5.4.6 Localization of proteins and amount of membrane helixes 
Prediction of localization of the proteins and amount of transmembrane helixes was 
made by TMHMM 2.0 server (Moller et al., 2001), prediction of signal peptide 
molecule with SignalP 3.0 server based on hidden Markov models (Emanuelsson et al., 
2007) and prediction of lipoproteins with LipoP (Junker et al., 2003). Clones with 
altered phenotype in AAG assay and the predictions of protein localization and amount 
of helixes are shown in table 5.1.  
 
Table 5.1. Localization of the proteins and possible signal peptide molecule predicted by TMHMM, 
SignalP and LipoP 
 
                                 Transmembrane                    Predicted  
Cj number Localization           helixes              signal peptide          Lipoprotein  
Cj0108  Outside   0   no  CYT 
Cj0121  Outside    0   no  CYT 
Cj0125c  Inside   0   no  CYT 
Cj0203  Inside and outside 12   no  TMH 
Cj0434  Outside   0   no  CYT 
Cj1223c  Outside   0   no  CYT 
Cj1717c  Outside   0   no  CYT 
TMH: Transmembrane helixes, SpI: Signal peptidase I, SpII: Lipoprotein signal pepdidase II, CYT: 
cytoplasmic or all the rest.  
  
The clones isolated in biofilm assay and HeLa cell adhesion assay where Cj0034c, 
Cj0404, Cj0408 Cj0525c and Cj0774c, examined in chapter 4, where it were predicted 
that Cj0034c, Cj0404 and Cj0525c contained one or more helixes. Cj0774c was 
predicted not to contain a helix but to be localized outside the cell but without signal 
peptides.  
 
5.5 Discussion 
C. jejuni is a common cause of bacterial food-borne disease, but the pathogenetic 
mechanisms are far from understood. However, it is shown in studies that AAG is 
associated with virulence. By use of a commercial ORF libray, expressing genes from 
C. jejuni NCTC 11168, we identified several genes that could be important for AAG, 
biofilm formation and adhesion in C. jejuni.  
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FlaA has in previously studies been recognised as required but not sufficient for 
autoagglutination and other therefore factors may be involved (Golden and Acheson, 
2002). We screened a commercial ORF library and identified 7 genes with possible 
associations to AAG. The genes were Cj0108 (atpC, ATP synthase subunit epsilon), 
Cj0121 (putative metalloprotease), Cj0125c (DnaK suppressor protein), Cj0203 
(putative citrate transporter), Cj0434 (pgm, phosphoglycerate mutase), Cj1223c (dccR, 
two component regulator) and Cj1717c (isopropyl malate isomerase leuC large 
subunit). Cj0203 has also been identified in a previously study screening for antigens of 
C. jejuni (chapter 4). The proteins were predicted to be localised outside except 
Cj0125c, that was predicted to be inside. One (Cj0203) was predicted to contain a helix. 
Cj1223c is a part of the two-component signal transduction system with Cj1222c, 
designated dccR-dccS. MacKichan et al (2004) showed that a mutant in both genes, 
respectively, reduced colonization and inflammatation of mice with limited flora but 
with no altered phenotypes in vitro assays. This indicates that the DccR (Cj1223c) 
response regulator may be required for growth within an in vivo environment. The 
genes identified in AAG study are mainly associated with energy production, 
metabolism and transport and a direct coupling with AAG is difficult. Other studies 
have likewise identified genes, beside flaA, to be associated with AAG. Golden and 
Acheson (2002) identified, by use of random transposon mutagenesis, Cj1318, Cj1333, 
Cj1340 and Cj1062 (putative CinA like protein) as being associated with AAG besides 
FlaA. Cj1318, Cj1333 and Cj1340 are clustered together and analysis of the 
surrounding DNA revealed genes involved in sialylation (Golden and Acheson, 2002). I 
order to verify the obtained results, the AAG positive clones should be repeated in a 
larger scale, such as glass tubes with a larger amount of volume and the possibility to 
measure OD of the supernatant.    
 
The screening for biofilm formation lead to several clones able to form biofilm but, due 
to sequencing problems, only few were identified; Cj0034 (putative periplasmic 
protein), Cj0404 (putative transmembrane protein), Cj0525c (pbpB, putative penicillin 
binding protein), Cj0774c (ATP transport system, ATP binding protein). The genes 
were also identified in the screening for antigens (chapter 4) and results were imported 
 65 
from the previously study described in chapter 4. That is probably the reason for the 
high number of antigens compared to the total number of clones producing biofilm. On 
the other hand, it is not unreasonably to suggest that proteins reacting with the immune 
system could be exposed to the surface of the bacteria and furthermore being expressed 
during infection. Therefore they could also be important for biofilm formation during 
colonization and persistent in the gastrointestinal track of the human host.  
 
Adhesion to epithelial cell is essential for C. jejuni and far from all adhesion factors, is 
known. We screened 288 E. coli clones for an enhanced ability to adhere, compared to 
the control and found one clone with a significantly improved adherence; Cj0408 
(frdC), a fumerate reductase. The gene is a part of the enzyme fumerate reductase which 
is a membrane bound enzyme catalyzing the reduction of fumerate (Weingarten et al., 
2009). There is no apparent link between adhesion to epithelial cell and the function of 
the enzyme, other than it is membrane bound and probably exposed to the surface and 
therefore could have a secondary function as adhesion factor.  
 
In general, it is hard to draw a direct line from these studies only made in E. coli to 
virulence associations in C. jejuni. But it can be indicated that high expressions of a 
particular protein could alter the behaviour of E. coli with gene insert compared to the 
control E. coli with no insert. An observed altered behaviour should of cause be studied 
in the originally bacteria, C. jejuni, before any conclusions on importance for virulence 
or host associations can be made. This leads to the perspectives and future work in this 
study, where specific mutants in NCTC11168 will be made and further tested in the 
same assays. Furthermore, additional work should be made in order to optimise the 
sequencing PCR and thereby be able to identify other genes with possible importance 
for virulence.  
 
We did identify genes that caused altered phenotypes in E. coli BL21(DE3) expressing 
various genes from C. jejuni compared to the E. coli BL21(DE3) without insert. The 
genes were found in autoagglutination assay, biofilm formation assay and adhesion 
assay. Our results suggest that specific virulence genes can be identified by using this 
clonal library. Due to sequencing difficulties and a limit amount of time, these genes 
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and their function in C. jejuni are not studied in further details.   
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Chapter 6. Identification of a fibronectin binding protein of 
Campylobacter jejuni 
 
6.1 Abstract 
Campylobacter jejuni is one of the most frequent bacterial causes of food borne 
gastrointestinal disease in developed countries. Previous studies indicated that binding 
of the bacteria to human intestinal cells is crucial in host colonization and disease. 
Fibronectin (Fn) is a 250 kDa glycoprotein abundant in the regions of cell-to cell 
contact in the gastrointestinal epithelium, where it mediates cell-cell contact and serves 
as a potential binding site for pathogens. It has earlier been shown that C. jejuni 
harbours two Fn binding proteins, CadF and FlpA and one putative Fn binding protein, 
Cj1349c. We have investigated the Cj1349c, which was both expressed and studied in 
E. coli and expressed and purified from E. coli, for its ability to bind Fn using an ELISA 
assay. The assays revealed a binding of Cj1349c to Fn and based on the data; we 
conclude that the Cj1349c protein has a role in attachment to host epithelial cells via Fn 
binding.   
 
6.2 Introduction 
Campylobacter jejuni is the leading cause of food borne human gastroenteritis in 
developed countries. Infection results in symptoms ranging from mild and watery 
diarrhoea to more severe diarrhoea with blood and leukocytes. The ability of C. jejuni to 
adhere and colonize the gastrointestinal tract of humans is proposed to be essential for 
disease (Wassenar and Blaser, 1999). Cell adherence is multifactorial and a number of 
adhesins have been identified, including JlpA (Jin et al., 2001), PEB1 (Pei et al., 1998), 
CapA (Ashgar et al., 2007), CadF (Konkel et al., 1997) and FlpA (Cj1279c) (Konkel 
2010). The target of CadF and FlpA was found to be Fn, a component of the 
extracellular matrix (Konkel et al., 1997, Konkel et al., 2010). 
 
Fn is a glycoprotein formed by two nearly identical 250 kDa subunits. The subunits are 
linked by disulfide bonds near their C termini. Each Fn monomer is composed of three 
types of repeating units; type I (~45 amino acids), type II (~60 amino acids) and type III 
(~90 amino acids) and each monomer contains 12 type I repeats, two type II repeats and 
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between 15 and 17 type III repeats (Pankov et al., 2002). Fn is involved in many 
interactions, including tissue repair, embryogenesis, blood clotting, and cell 
migration/adhesion. Two forms of Fn exists: the soluble plasma Fn synthesised by 
hepatocytes and the insoluble Fn involved in host cell extracellular matrix (ECM) 
interaction synthesised by chondrocytes, fibroblasts, endothelial cells, macrophages and 
some epithelial cells (Pankov et al., 2002). Fn serves as a eukaryotic molecule 
connecting cells to ECM components, such as collagen and other proteoglycan 
substrates. The abundance of Fn in regions of cell-to-cell contact in the gastrointestinal 
epithelium makes it a potential binding site for intestinal pathogens. The invasion of Fn 
binding bacteria is potentially enhanced by the interaction of Fn and α5β1 integrins, 
which stimulate rearrangement in the cytoskeleton and membrane protrusion that 
facilitate the process of internalization and spreading of the bacteria (Gilcrease, 2007). 
 
Several bacterial pathogens are known to bind Fn, including Staphylococcus aureus 
(Kuusula et al., 1978), Streptococcus pyogenes (Myhre and Kuusula, 1983), Salmonella 
enteritidis (Baloda et al., 1985), Escherichia coli (Fröman et al., 1984), Neisseria 
gonorrhoeae (van Putten et al., 1998), Mycobacterium avium (Schorey et al., 1996) and 
C. jejuni (Kuusula et al., 1989; Konkel et al., 1997; Konkel et al., 2010), which 
emphasises the importance of investigating the mechanism of Fn binding. Besides to the 
known proteins, CadF and FlpA, an additional putative Fn binding protein (Cj1349c) 
was annotated in C. jejuni Parhill et al., 2000). In this study, we investigate this protein 
for its ability to interact with Fn.   
 
6.3 Material and methods 
6.3.1 Bacteria and growth conditions 
E. coli BL21(DE3) (Cj1349c-pET24b(+)) and BL21(DE3) (Cj1349c-pTLJ03) (Parrish 
et al., 2004) were grown aerobically on or in Luria-Bertani (LB) plates or broth 
supplemented with ampicillin (Amp) (100 µg/ml). Campylobacter strains were cultured 
on Mueller-Hinton agar plates supplemented with 5 % bovine blood under microaerobic 
conditions (5 % O2, 10 % CO2, 85 % N2) at 37 °C for 48 hours.   
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6.3.2 Fibronectin binding assay with glass cover slides 
Cover glass slides were coated with 40 µl bovine Fn (10 µg/ml) (Sigma) and air-dried 
over night. The cover glass slides were washed in PBS and incubated with BSA for 1 
hour and washed with PBS again. E. coli BL21 (Cj1349c-pTLJ03) and E. coli BL21 
(Cj1279c-pTLJ03) were induced over night in MagicMedia (Invitrogen) at 37 °C. 0.5 
ml overnight cultures were adjusted OD600 = 1.5 in PBS and added the cover glass 
slides coated with Fn. C. jejuni were grown microaerobic at 37 °C for 48 hours, then 
adjusted OD600 = 1.0 in PBS and 0.5 ml were added the cover glass slides coated with 
Fn. The cover glass slides were incubated for two hours (microaerophilic for C. jejuni 
and at 37 °C for both E. coli and C. jejuni) and washed several times with PBS. Binding 
to Fn was visualised with crystal violet (0.1 %) staining.  
 
6.3.3 Generation of E. coli BL21 (DE3) (Cj1349c) 
Expression vector pET24b(+) (KanR), harbouring a full length Cj1349c gene, was PCR 
amplified from C. jejuni NCTC 11168 chromosomal DNA using primers Cj1349c-F1 
(5’-ATATAGAGCTCCTCTTACTCGTGCAATGAGTGC) (SacI site underlined) and 
Cj1349c-R1 (5’-ATATACTCGAGAATACTTTTAAAATTTGTATAATTTACAA) 
(XhoI site underlined). PCR was performed by 1 cycle of 4 min at 95 °C, 30 cycle of 1 
min at 95 °C, 1 min at 55 °C and 1 min 72 °C, followed by 10 min at 72 °C. PCR 
products were verified on a 1 % agarose gel. The bands were cut out and purified by gel 
extraction kit (Qiagen), digested with BamH1 and EcoR1 and ligated into the equivalent 
sites of the pET24b(+) downstream of the T7 Lac promoter and the upstream of His
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 tag 
to produce a plasmid pET24b(+)-Cj1349c for protein overproduction. The ligation 
mixture was ethanol precipitated before electroporation into E. coli BL21(DE3).    
 
6.3.4 Generation of 5 fragments of Cj1349c gene  
Fragments of the Cj1349c gene were constructed in pET24b(+) as described for 
generation of E. coli BL21 (DE3) (Cj1349c). The 435 residues were divided into 5 
fragments by the residues and primers. Fragment 1: 45-240 (primer F1 and R1), 
fragment 2: 45-320 (primer F1 and R2), fragment 3: 45-435 (primer F1 and R3), 
fragment 4: 150-320 (primer F2 and F3) and fragment 5: 320-435 (primer F3 and R3). 
SacI restriction site was added forward primer and XhoI added reverse primer. Primer 
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for the generation (5’):  
F1: ATATAGAGCTCTCTTACTCGTGCAATGAGTGC 
F2: ATATAGAGCTCTAATGTGATTTTAGAGTCTTTAAAGC 
F3: ATATAGAGCTCTCATAAACAAGAAGATCTTGTCGC 
R1: ATATACTCGAGTTTGCCTTCAAAATCATCAAGC 
R2: ATATACTCGAGAATTTTAAACTCGTTTAAAATAAAAATTTGC 
R3: ATATACTCGAGAATACTTTTAAAATTTGTATAATTTACAA 
 
6.3.5 Expression and purification of recombinant Cj1349c protein 
An overnight pre-culture of E. coli BL21(DE3) containing the pET24b(+) plasmid 
(Novagen) was 50-fold diluted to inoculate 1000 ml LB medium containing 30 µg/ml 
kanamycin. The culture was incubated with shaking at 37 °C to an OD600 of 0.5, then 
induced with 10 mM IPTG and incubated with shaking for 16 hours at 30 °C. After 
induction, cells were lysed on ice in 20 ml lysis buffer (50 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidadole, 10 % glycerol) by addition of 1 mg/ml lysozyme followed by 
sonication. Lysates were cleared by centrifugation at 15,000xg for 30 min. His-tagged 
Cj1349c proteins were purified by nickel affinity chromatography using the Ni-NTA 
resin (Qiagen) equilibrated with lysis buffer. Cj1349c protein was eluted with 250 mM 
imidazole.  
 
6.3.6 Fibronectin binding assay with purified protein 
The wells of a 96-well plate were coated over night at 4 °C with either 1 µg of human 
Fn (Sigma) or BSA, which served as a negative control. The following day, the wells 
were rinsed with wash buffer (PBS containing 0.001 % Tween 20), blocked with 1% 
BSA for 2 h at 25 °C and rinsed once with wash buffer. To determine the Fn binding 
activity of the protein, twofold serial dilutions of Cj1349c, FlpA and CadF proteins 
were made in PBS, added to the wells, and incubated for 2 h at 25 °C. The CadF protein 
was used as a positive control for Fn binding affinity. After the wells were washed three 
times with wash buffer, a 1:1000 dilution of rabbit anti-His (Sigma) in incubation buffer 
was added to the wells and the plate was incubated at 25 °C for 1 h. The wells were then 
washed three times with wash buffer, a 1:5000 dilution of horseradish peroxidase 
labeled goat anti-His antibody (Sigma) diluted in PBS was added to the wells, and the 
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plate was incubated at 25 °C for 30 min. The wells were then washed, and bound 
antibodies were detected by addition of TMB substrate solution (Thermo Scientific). 
Binding was quantified by colorimetric detection at 492 nm.    
 
6.3.7 Preparation of polyclonal antisera 
Female New Zealand White rabbits were subcutaneously injected with 100 µg of 
purified Cj1349c protein in TiterMax Gold extract. A booster injection of 50 µg 
natively purified protein in Freund´s incomplete adjuvant (Sigma) was given after 4 
weeks. Blood was collected prior to the first and second immunizations, and 2 weeks 
after the second immunization. Sera were stored at -20 °C.   
 
6.3.8 Immuno-fluorescence microscopy 
Bacteria were grown microaerophilic 48 h at 37 °C. Then harvested at 4000 rpm and 
resuspended in 100 µl 4 % formalin in PBS. The cells were fixed 20 min at 4oC, 
followed by washing with PBS. Appropriate amount of fixed bacteria were added to 
single wells of a poly-L-lysine coated six-well glass slide (Novakemi Ab) and air-dried. 
The slide was washed in PBS for 10 min using a coplin jar. Primary polyclonal 
antibodies raised against Cj1349c in rabbit (see above) were diluted in PBS to a final 
ration of 1:100, 1:300 and 1:1000 and added to each well on the glass slide followed by 
incubation in a humid chamber for 45 min. After washing in PBS (in coplin jar), Cy3 
conjugated secondary anti-rabbit antibodies (Alexa Fluor® 4594, goat anti-rabbit IgG, 2 
mg/ml, Invitrogen) were diluted in a 1:500 ration and added to each well on the glass 
slide and incubated in a dark humid chamber. In the following steps, the glass slide was 
kept in the dark. After washing, the slide was air-dried and cover slips mounted in 
VECTASHIELD® Mounting Medium (Vector Laboratories, Burlingame, CA, USA). 
Finally, the slide was examined with epifluorescence microscopy using the Cy3 
spectrum of light for the fluorophore. 
 
6.4 Results 
6.4.1 Fibronectin binding assay with E. coli cells on glass cover slides 
To study the ability of Cj1349c to bind Fn, the gene was over-expressed in E. coli and 
the ability of the E. coli to bind to Fn coated glass slides was tested. This resulted in 
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strong and reproducible binding to Fn of E. coli BL21(DE3) Cj1349c compared to E. 
coli BL21(DE3) (figure 6.1 A-C). FlpA (Cj1279c) was further included as a control and 
binding was confirmed but found weaker compared to Cj1349c.                                                                                                                   
  
 
  
 
 
  
 
 
Figure 6.1. Fibronectin binding to glass slides. A. Glass slides coated with bovine fibronectin (40 µl 
fibronectin (10 µg/ml)) and added 0.5 ml overnight induced E. coli BL21(DE3) expressing Cj1349c. B. E. 
coli BL21(DE3) expressing FlpA (Cj1279c). C. E. coli BL21(DE3) with no insert.  
 
6.4.2 Fibronectin binding assay with purified protein 
Purified Cj1349c protein was used in an ELISA assay with microtiter plates coated with 
Fn. The results showed a relatively strong binding of purified Cj1949c protein to Fn. 
CadF was included as a control in this study exhibiting a high dose dependent binding 
compared to Cj1349c (figure 6.2). The binding of FlpA (Cj1279c) was found to be 
weaker which correlates with the results seen in the glass slide assay shown in figure 
6.1.   
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Figure 6.2. Fibronectin binding to purified protein. ELISA assay demonstrating the binding capacity 
of Cj1349c, CadF, FlpA (Cj1279c) and a control respectively. Y-axis presents OD
492
 and X-axis the 
dilution row of Fn. As a control BSA was used. The binding capacity of Cj1349c was relatively strong 
and dose dependent compared to Cj1279c, but not as strong as for CadF. 
 
5.4.3 Immuno-fluorescence microscopy 
To test the specificity of the antiserum against Cj1349c made in rabbits, an immuno-
fluorescence microscopy experiment was carried out. It was not possible to see any 
specific antibody binding using this assay. 
 
6.5 Discussion and perspectives 
Adherence to gastrointestinal cells and extracellular matrix components has previously  
been found crucial for C. jejuni for host interaction and disease. More particularly Fn, a 
component of the extracellular matrix, has been found to be an adhesion receptor for the 
C. jejuni proteins CadF and FlpA (Konkel et al., 1997; Konkel et al., 2010). Another C. 
jejuni protein has been annotated as a putative Fn binding protein and in this study we 
have shown its ability to bind Fn.  
 
To assess the binding of Cj1349c to fibronectin, binding assays of whole bacterial to Fn 
1 1:2 1:4 1:64 1:8 1:16 1:32 0 
1 1:2 1:4 1:64 1:8 1:16 1:32 0 1 1:2 1:4 1:64 1:8 1:16 1:32 0 1 1:2 1:4 1:64 1:8 1:16 1:32 0 
1 1:2 1:4 1:64 1:8 1:16 1:32 0 
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and an ELISA was used. The protein was expressed in E. coli in order to purify the 
protein to be used in ELISA. The assays showed consistency by revealing that Cj1349c 
binds to Fn and it binds relatively stronger than FlpA (Cj1279c). The assay was also 
attempted for C. jejuni NCTC 11168 but with no visual Fn binding. The binding of C. 
jejuni to Fn has previously been shown in C. jejuni F38011 (Konkel, M., personal 
communication) and the reasons for the failure in NCTC 11168 may be due to a lower 
expression level in NCTC 11168 or that it needs different growth or induction 
conditions. Both NCTC 11168 and F38011 are clinical isolates from patients diagnosed 
with C. jejuni but as previously reported, NCTC 11168 has changed phenotypes since 
the isolation, which could also be an explanation (Gaynor et al., 2004).  
 
The ability of FlpA (Cj1279c) and Cj1349c to bind epithelial cells in vitro has been 
investigated previously (Flanagan et al., 2009). This study revealed a significant 
reduction of both the mutants of FlpA and Cj1349c to bind LMH chicken hepatocellular 
carcinoma epithelial cells. Furthermore, a chicken colonization experiment showed the 
FlpA mutant, but not the Cj1349c mutant, to be attenuated for colonization (Flanagan et 
al., 2009). CadF has likewise been shown to be important for chicken colonization 
(Ziprin et al., 1999). The different chicken colonization behaviour of the CadF, FlpA 
and Cj1349c mutants indicate the Fn binding proteins have different, and potentially 
host-specific functions, in the interaction with host cells. It can therefore not be 
excluded that Cj1349c is important for the virulence of C. jejuni in humans, and to 
pursue this hypothesis, investigations are in process to study the interactions of Cj1349c 
with human epithelial cells (results not shown). It is possible that expression of Cj1349c 
may need a host specific induction factor not taken into account in this experiment.  
 
The domain on CadF with maximal Fn-binding activity has been localized to four 
amino acids (AA 134-137) consisting of the residues phenylalanine-arginine-leucine-
serine (FRLS) (Konkel et al., 2005). We have constructed 5 E. coli clones each 
expressing a fragment of the Cj1349c protein and Fn-binding assays with these clones 
may reveal a novel C. jejuni binding site.  
 
We have shown that the putative Fn binding protein, Cj1349c, binds to Fn in a glass 
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slide assay with E. coli expressing the protein and with purified protein in an ELISA 
assay. The binding domain of the protein to Fn and its biological importance is subject 
to ongoing research.  
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7. Discussion and future perspectives 
During this PhD study (chapter 3, appendix 2), we demonstrated that Danish C. jejuni 
isolates were genetically highly diverse by the use of MLST. Analysis of isolates from 
patients diagnosed with reactive arthritis were associated to many different clonal 
complexes, which suggest that this sequela rather involves differential expression of 
virulence factors. Analysis of isolates from GBS patients showed that these isolates 
were significantly over-represented in the ST-22 complex, which was also suggested 
previously (Dingle et al., 2001a). Previous studies, using MLEE typing, ribotyping, 
PFGE typing, flagellin gene typing and DNA Microarray found a significant diversity 
among GBS-related strains in contrast to our findings (Engberg et al., 2001; Leonard et 
al., 2004). A recent study, characterizing isolates from Bangladesh, identified the ST-
403 complex to be correlated with GBS and further they found the ST-22 complex only 
in GBS isolates and not enteritis isolates (Islam et al., 2009). Penner heat-stabile (HS) 
serotype HS:19 has previously been associated with the development of GBS and the 
risk of developing GBS after infection with C. jejuni of serotype HS:19 was found to be 
several fold higher than with other serotypes (Nachamkin et al., 1998; Engberg et al., 
2001). Islam et al (2009), in contrast, found the HS:23 strain to be dominant for GBS 
isolates in Bangladesh. Interestingly, the ST-403 complex belongs only to serotype 
HS:23 and ST-22 complex isolates belong only to the serotype HS:19. That is also the 
case for the isolates in this study, where five GBS isolates, belonging to ST-22 clonal 
complex, were Penner HS:19 serotyped (appendix 2). The study by Dingle et al (2001b) 
also had a overrepresentation of the serotype HS:19 in ST-22 clonal complex.  These 
studies could indicate that HS:19 and ST-22 complex and HS:23 and ST-403, 
respectively, have clonal population structures. The studies further suggest that these 
groups might have unique virulence properties and that putative neuropathogenic C. 
jejuni serotypes and clonal complexes may circulate in different geographic areas. Also 
the LOS locus class A has been strongly associated with GBS outcome in several 
studies (Nachamkin et al., 2002; Islam et al., 2009) and it should also be kept in mind 
that differences in clinical outcome are likely to be attributable to differences in host 
background. It was proposed by the results from a family outbreak, in which one of 
three individuals with C. jejuni enteritis developed GBS and had a significant difference 
in the immune response towards LOS (Ang et al., 2000). Therefore, several factors 
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seem to be involved in the development of GBS, and the studies taken together could 
suggest an increased risk of GBS with certain clonal complexes perhaps in combination 
with a certain serotype, expression of the right LOS in combination with host responses. 
The fact that C. jejuni is naturally competent means that C. jejuni populations are 
subject to high rates of horizontal gene exchange with recombinational events 
contributing to a significant proportion of allelic diversity (Suerbaum et al., 2001; 
Schouls et al., 2003). This should also be taken into account when assessing the 
effectiveness of genotyping.  
 
Although C. jejuni is the major cause of gastroenteritis worldwide little is known about 
its pathogenesis. Therefore, detection and identification of new virulence factors are 
crucial for this pathogen. The definition of a virulence factor can be divided into three; 
1) true virulence genes (coding for factors or enzymes producing factors involved in all 
the processes of interaction with the host, responsible for the pathological damage 
during infection and absent in non-pathogens), 2) virulence associated genes (coding for 
factors or for enzymes producing factors that regulate expression of virulence genes or 
activate virulence factors or are required for the activity of true virulence factors) and 
finally, 3) virulence life-style genes (factors that enable the colonization of the host, 
evasion of the host immune system, intracellular survival or employ host-factors for the 
benefit of survival) (Wassenaar and Gaastra, 2001).  
 
Virulence factors are often immunogenic as a result of the acquired immunesystem 
producing protective antibodies against virulence gene products (Wassenaar and 
Gaastra, 2001). We used this approach in our second study (manuscript 2, chapter 4), 
searching for both antigens in the purpose of vaccine development and in the search for 
new virulence genes. As vaccine candidates, the strategy is more straightforward. If the 
acquired immune system recognises the proteins, the product is specific and conserved 
for the targeted pathogen and easy to handle, express and isolate, then you have a 
possible good vaccine candidate. Several studies have been made and are still in 
progress in order to develop a vaccine against C. jejuni either for chickens thus 
indirectly reducing the number of human infections or for humans. Our study, described 
in manuscript 2, chapter 4, targeted for the latter. We identified 25 immunogenic 
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proteins in our screen. Five of them were tested as vaccine candidates by challenge 
experiments in mice; one of them, SSI-3, showed promising results by reducing 
invasion into the spleen and liver and some against colonization. Other studies have 
identified proteins for vaccine development, some associated with the C. jejuni surface 
and several of them are identical to proteins identified in this study. They are discussed 
in maunscript 2, chapter 4. Some of the identified antigenic proteins in this thesis have 
been predicted to be cytoplasmic proteins. This has also been shown in other studies. 
The cell binding factor, PEB4 (encoded by Cj0596) is immunogenic and located in the 
periplasma (Dubreuil et al., 1990) and is important for invasion and colonization 
(Rathbun et al., 2009). Also, the highly virulent lipoprotein cjaA (Cj0982c) has been 
identified to be localized in the inner membrane and further a promising vaccine 
candidate (Wyszynska et al., 2004, 2008). Prokhorova et al (2006) found several 
cytoplasmic proteins (ribosomal etc.) when identifying possible vaccine candidates. 
Immune responses directed against cytoplasmic proteins can be explained by a natural 
occurring lysis of the bacteria and thereby exposure of the proteins or that the protein is 
secreted. Another explanation may be the role of dendritic cells as antigen presenters, 
where the bacteria are probably broken down and presented by the dendritic cells. Other 
studies have also used E. coli libraries to identify immuno-reactive proteins. Connerton 
and Connerton (1999) used a lambda phage expression library and identified an integral 
membrane protein; amaA and Galindo et al (2001) identified, by the use of a cosmid 
library, an 80-kDa antigen. The method has also been applied to other pathogens; 
Padmalayam et al (2000) identified an immunogenic lipoprotein of Bartonella 
bacilliformis, and Werner et al (2006) identified an immuno-dominant antigen of 
Bartonella henselae by constructing cosmid libraries.  
 
Even though the argument that virulence factors are often immunogenic cannot be 
directly reversed (Wassenaar and Gaastra, 2001), we tested if our immunogenic proteins 
could be associated with virulence. It cannot be reversed because some immunogenic 
proteins are solely structural components of the bacterial cell. Chaperons, for example, 
can raise an antibody response and have adherence properties to epithelial cells 
(Brøndsted et al., 2005) but their function in stress repair and folding is of greater 
significance than their virulence properties (Wassenaar and Gaastra, 2001). On the other 
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hand, proteins needed for infection are most likely expressed at high levels during 
infection and are therefore, possible targets for the immune system. Some of the 
immunogenic proteins, identified in manuscript 2, chapter 4, were studied in an 
adhesion assay in their natural host, C. jejuni NCTC11168 as knock-out mutants and 
one protein seemed particular interesting (Cj0034c). The protein was further analysed 
for altered motility, autoagglutination, biofilm formation, and serum resistance but with 
no altered phenotypes. We further studied the protein in an animal mouse model but 
neither the C. jejuni wildtype nor the mutant succeeded in colonization (data not 
shown). In the studies described in both manuscript 2 and 3 (chapter 4 and 5), we have 
faced one of the probably most common obstacles, when studying C. jejuni virulence 
factors; the lack of a solid and reproducible animal model that could prove the 
association between the proteins and adhesion, colonisation and possible virulence. 
Another study has identified an adhesion protein without proving its role in an animal 
model (Jin et al., 2001). The JlpA (jejuni lipoprotein A) was seen to be surface-exposed 
but not immunogenic, mutants of this protein had reduced adherence to HEp-2 cells and 
antibodies against JlpA inhibited the binding in a dose dependent manner. These results 
taken together demonstrated the JlpA protein to be an adhesion factor. To show that 
protein Cj0034c was an adhesion factor, we should complement the knock-out mutant 
and show its re-established binding to INT407 epithelial cell. Further, we could produce 
antibodies against the protein and examine a possible binding inhibition to the epithelial 
cell. Furthermore, the localisation of the protein and target molecule on the host cells 
would be of great interest. Several other identified genes in manuscript 2 and 3 could be 
important for C. jejuni interaction with the human host or for survival strategies such as 
biofilm formation, and further studies will be made in order to confirm the results.  
 
Flagellin has previously been shown to be a strong antigen and also important for 
autoagglutination (Cawthraw et al., 1994; Guerry et al., 2006), therefore it is striking 
that it has not been identified in either the antigen or the autoagglutination screening. 
An explanation can be how the expression library was constructed. A pool of the 
original vectors from the E. coli strains was purified and then transformed to the 
BL21(DE3) expression strain. During this purification step the flagellin gene, among 
other, could be lost or it could have been lost during the transformation step into E. coli 
BL21.  
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In the study, outlined in manuscript 4, chapter 6, we used another approach in order to 
identify proteins important for host interaction. A protein predicted to be an adherence 
factor with a known target molecule was studied. We showed that the protein, expressed 
by the Cj1349c gene, did bind to fibronectin when expressed in E. coli and when 
purified. Binding to fibronectin is important for C. jejuni and adhesion to the host. The 
importance of CadF and FlpA has been proved by adherence to human epithelial cells 
and for colonization in chickens (Konkel et al. 1997; Flanagan et al., 2009). Cj1349c 
does also bind to human epithelial cells but has no effect on chicken colonization. It can 
still not be excluded that Cj1349c is important for human host interaction, by adhesion 
and a possible activation of integrins, rearrangement of cytoskeleton and thereby 
possible invasion of the bacteria. We have produced antibodies against Cj1349c but as 
there was no binding in fluorescence microscopy we speculate if the serum is specific 
enough. The lack of binding could also be caused be a low expression level of Cj1349c 
on C. jejuni and we need to confirm our speculation by a western blot with purified 
protein and the serum with antibodies raised against purified Cj1349c. It is also possible 
that the transcription of the Cj1349c protein are triggered by different culture conditions 
and it has been shown that the protein was upregulated when C. jejuni was cultured with 
the bile acid deoxycholate (Malik-Kale et al., 2008).  
 
Even though we have contributed to the knowledge regarding C. jejuni and host 
interactions by identifying novel putative surface proteins, finding a possible vaccine 
candidate and verifying a new fibronectin binding protein, further analysis needs to be 
done on these proteins to verify their exact role in the C. jejuni pathogenesis. Regarding 
the pathogenesis of C. jejuni in general, much work is also needed to identify the 
reasons why this bacterium is so successful when it comes to human infections despite 
its relatively demanding growth requirements. Probably we need to move focus from 
known virulence factors and methods utilised assessing pathogenesis in other bacteria 
and focus on human host responses and novel methods. Furthermore, genomic 
sequencing and comparison of C. jejuni strains will probably contribute with important 
insight into the C. jejuni pathogenesis.   
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8. Overall conclusion 
In conclusion, the experimental studies included in this thesis have shown a possible 
correlation between a MLST clonal complex and the severe clinical post infection, 
Guillain-Barré syndrome. The method was useful to study the population clonality of C. 
jejuni, and un-typeable strains were not identified. We identified several immunogenic 
proteins of C. jejuni of which one is a possible vaccine candidate and one may be 
associated to cell adherence in the human host. We also found proteins involved in 
survival mechanisms, such as biofilm-formation, which could be of great interest to 
further studies. We showed that screening of an E. coli library is a very effective way in 
order to identify new antigens or surface exposed proteins. Additionally, we showed 
that the putative fibronectin binding protein encoded by Cj1349c, indeed did bind to 
fibronectin and could be of significant importance to human host interactions.  
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Supplementary to paper:  
A number of the Guillain-Barré isolates have been Penner serotyped in a previous study 
(Nachamkin et al., 2002). 
 
Original strain This study Serotype Clonal complex  
KB3449  1575  HS:19  22 
OH4382  1576  HS:19  22 
INP7   1577  HS:19  22 
HB9635  1578  ND  354 
INP59   1579  HS:41  42 
HB96-43  1580  HS:19  22 
HB95-29  1581  HS:19  22 
INP21   1582  HS41  42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
